

BIBLIOGRAPHY

1. Abedi D., Feizizadeh S., Akbari V., Jafarian-Dehkordi A. 2013. *In vitro* anti-bacterial and anti-adherence effects of *Lactobacillus delbrueckii* subsp *bulgaricus* on *Escherichia coli*. Res Pharm Sci 8 (4): 260-268.
2. Abreu MT., Fukata M., Arditi M. 2005. TLR signalling in the gut in health and disease. J Immunol 174: 4453-4460.
3. Abreu MT., Vora P., Faure E., Thomas LS., Arnold ET., Arditi M. 2001. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol 167: 1609-1616.
4. Acharya MR., Sparreboom A., Venitz J. 2005. Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol 68: 917-932.
5. Acheson DWK., Donohue-Rolfe A., Keusch GT. 1991. The family of Shiga and Shiga-like toxins. In Sourcebook of bacterial protein toxins. Academic Press, New York, USA, 415-433.
6. Agrawal A., Khan MH., Whorwell PJ. 2009. Irritable bowel syndrome in the elderly: An overlooked problem? Dig Liver Dis 41: 721-724.
7. Ahmed AM, Furuta K., Shimomura K., Kasama Y., Shimamoto T. 2006. Genetic characterization of multidrug resistance in *Shigella* spp. from Japan. J Med Microbiol 55: 1685-1691.
8. Akira S., Takeda K., Kaisho T. 2001. Toll-like receptors: critical proteins linking innate and acquired immunity. Nutr Immunol 2 (8): 675-680.
9. Akira SH., Takeda K., Dong Z., Modlin RL., Takeuchi O., Sato S., Horiuchi T., Katsuaki K. 2002. Lipoproteins mediating immune response to microbial cutting edge: role of Toll-Like Receptor 1. J Immunol 169: 10-14.
10. Akira S., Uematsu S., Takeuchi O. 2006. Pathogen recognition and innate immunity. Cell 124: 783-801.
11. Alander M., Satokari R., Korpela R., Saxelin M., Vilpponen-Sal T., Mattila-Sandholm T., Von Wright A. 1999. Persistence of colonization of human colonic mucosa by a probiotic strain, *Lactobacillus rhamnosus* GG, after oral consumption. Appl Environ Microbiol 65: 351-354.

12. Allameh SK., Daud H., Yusoff FM., Saad C., Ideris A. 2012. Isolation, identification and characterization of *Leuconostoc mesenteroides* as a new probiotic from intestine of snakehead fish (*Channa striatus*). *Afr J Biotechnol* 11 (16): 3810-3816.
13. Alm L. 1982. Effect of fermentation on lactose, glucose and galactose content in milk and suitability of fermented milk products for lactose-deficient individuals. *J Dairy Sci* 65: 346-352.
14. Alvarez S., Villena J., Tohno M., Salva S., Kitazawa H. 2009. Modulation of innate immunity by lactic acid bacteria: impact on host response to infections. *Curr Res Immunol* 3: 87-126.
15. Andriulli A., Mangia A., Iacobellis A., Ippolito A., Leandro G., Zeuzem S. 2008. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. *Aliment Pharmacol Ther* 28 (4): 397-404.
16. Antikainen J., Korhonen TK., Kuparinen V., Toba T., Ross S. 2009. Surface proteins of *Lactobacillus* involved in host interactions. In: *Lactobacillus* molecular biology: from genomics to probiotics, Caister Academic Press, Norfolk, UK, 95-114.
17. Apostolou E., Kirjavainen PV., Saxelin M., Rautelin H., Valtonen V., Salminen SJ., Ouewhand AC. 2001. Good adhesion properties of probiotics: a potential risk for bacteremia? *FEMS Immunol Med Microbiol* 31 (1): 35-39.
18. Araujo TF., Ferreira CL. 2013. The genus *Enterococcus* as probiotic: safety concerns. *Braz Arch Biol Technol* 56 (3): 457-466.
19. Arbibe L., Kim DW., Batsche E., Pedron T., Mateescu B., Muchardt C., Parsot C., Sansonetti PJ. 2007. An injected bacterial effector targets chromatin access for transcription factor NF-kappaB to alter transcription of host genes involved in immune responses. *Nutr Immunol* 8: 47-56.
20. Arokiyaraj S., Islam VIH., Bharanidharan R., Raveendar S., Lee J., Kim DH., Kyooh Oh Y., Kim E., Kim KH. 2014. Antibacterial, anti-inflammatory and probiotic potential of *Enterococcus hirae* isolated from the rumen of *Bos primigenius*. *World J Microb Biot* 30 (7): 2111-2118.
21. Arondel J., Singer M., Matsukawa A., Zychlinsky A., Sansonetti PJ. 1999. Increased interleukin-1 (IL-1) and imbalance between IL-1 and IL-1 receptor antagonist during acute inflammation in experimental shigellosis. *Infect Immun* 67: 6056-6066.

22. Arora S., Kaur I., Chopra K., Rishi P. 2014. Efficiency of double layered microencapsulated probiotic to modulate pro-inflammatory molecular markers for the management of alcoholic liver disease. *Mediat Inflamm* Article ID 715130.
23. Arseneau KO., Tamagawa H., Pizarro TT., Cominelli F. 2007. Innate and adaptive immune responses related to IBD pathogenesis. *Curr Gastroenterol Rep* 9 (6): 508-512.
24. Artursson P. 1990. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. *J Pharmaceutical sci* 79: 476-482.
25. Ashkenazi S. 2004. *Shigella* infections in children: new insights. *Semin Pediatr Infect Dis* 15: 246-252.
26. Ashkenazi S. 2004. *Shigella* Infections in Children: New Insights. *Semin Pediatr Infect Dis* 15: 246-252.
27. Ashkenazi S., Dinari G., Zevulunov A., Nitzan M. 1987. Convulsions in childhood shigellosis. Clinical and laboratory features in 153 children. *Am J Dis Child* 141: 208-210.
28. Aureli P., Capurso L., Castellazzi AM., Clerici M., Giovannini M., Morelli L., Poli A., Pregliasco F., Salvini F., Zuccotti GV. 2011. Probiotics and health: an evidence-based review. *Pharmacol Res* 63 (5): 366-376.
29. Avall-Jaaskelainen., Palva A. 2005. *Lactobacillus* surface layers and their applications. *FEMS Microbiol Rev* 29: 491-590.
30. Avital A., Maayan C., Goitein KJ. 1982. Incidence of convulsions and encephalopathy in childhood *Shigella* infections. *Clin Pediatr* 21: 645-648.
31. Axelsson L. 1998. Lactic acid bacteria: classification and physiology. In: *Lactic Acid Bacteria: microbiology and functional aspects*, Marcel Dekker Inc, New York, NY, USA, 1-72.
32. Axelsson LT. 1993. Lactic Acid Bacteria: Classification and Physiology. In: *lactic Acid bacteria*, Marcel Dekker, New York, NY, USA, 1-64.
33. Axelsson LT., Ahrne SE., Andersson MC., Stahl SR. 1988. Identification and cloning of a plasmid-encoded erythromycin resistance determinant from *Lactobacillus reuteri*. *Plasmid* 20 (2): 171-174.
34. Azim T., Chandra Halder R., Safiullah Sarker M., Ahmed S., Hamadani J., Chowdhury A., Qadri F., Salam MA., Sack B., Albert M. 1995. Cytokines in the stools of children with complicated shigellosis. *Clin Diagnostic Laboratory Immunol* 2 (4): 492-495.

35. Baarlen VP., Troost FJ., Hemert S., Meer VC., de Vos WM., de Groot PJ., Hooiveld GJ., Brummer RJ., Kleerebezem M. 2009. Differential NF-kappaB pathways induction by *Lactobacillus plantarum* in the duodenum of healthy humans correlating with immune tolerance. *Proc Natl Acad Sci* 106 (7): 2371-2376.
36. Baccigalupi L., Di Donato A., Parlato M., Luongo D., Carbone V., Ricca E., De Felice M. 2005. Small surface-associated factors mediate adhesion of a food-isolated strain of *Lactobacillus fermentum* to Caco-2 cells. *Res Microbiol* 156 (7): 830-836.
37. Bai AP., Ouyang Q., Xiao XR., Li SF. 2006. Probiotics modulate inflammatory cytokine secretion from inflamed mucosa in active ulcerative colitis. *Int J Clin Pract* 60: 284-288.
38. Bai AP., Ouyang Q., Zhang W., Wang CH., Li SF. 2004. Probiotics inhibit TNF-alpha-induced interleukin-8 secretion of HT29 cells. *Shijie Huaren Xiaohua Zazhi* 10: 455-457.
39. Bailey RW., Scott EG. 1966. *Diagnostic microbiology*, 2nd ed., St. Louis CV Mosby Company, Missouri, USA, 330-331.
40. Balter-Seri J., Yuhas Y., Weizman A., Nofech-Mozes Y., Kaminsky E., Ashkenazi S. 1999. Role of nitric oxide in the enhancement of pentylenetetrazole-induced seizures caused by *Shigella dysenteriae*. *Infect Immun* 67: 6364-6368.
41. Banchereau JSR. 1998. Dendritic cells and the control of immunity. *Nutr* 392: 245-252.
42. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu YJ, Pulendran B, Palucka K. 2000. Immunobiology of dendritic cells. *Annu Rev Immuno* 118: 767-811.
43. Barker SB., Summerson WH. 1941. The calorimetric determination of lactic acid in biological material. *J Biol Chem* 138: 535-554.
44. Barrett Connor E., Connor JD. 1970. Extra intestinal manifestations of Shigellosis. *Am J Gastroenterol* 53: 234-237.
45. Barros RR., Carvalho GS., Peralta JM., Facklam RR., Teixeira LM. 2001. Phenotypic and genotypic characterization of *Pediococcus* strains isolated from human clinical sources. *J Clin Microbiol* 39 (4): 1241-1246.
46. Basu S., Paul DK., Ganguly S., Chatterjee M., Chandra PK. 2009. Efficacy of high-dose *Lactobacillus rhamnosus* GG in controlling acute watery diarrhea in Indian children: a randomized controlled trial. *J Clin Gastroentero* 143: 208-213.
47. Beckman JS., Beckman TW., Chen J., Marshall PA., Freeman BA. 1990. Apparent hydroxyl radical production by peroxynitrite: implication for endothelial injury from nitric oxide and superoxide. *Proc Natl Acad Sci USA* 87: 1620-1625.

48. Ben-Neriah Y. 2002. Regulatory functions of ubiquitination in the immune system. *Nutr Immunol* 3: 20-26.
49. Bengmark S. 1998. Ecological control of the gastrointestinal tract-the role of probiotic bacteria. *Gut* 42 (1): 2-7.
50. Benjelloun-Touimi Z., Tahar MS., Montecucco C., Sansonetti PJ., Parsot C. 1998. SepA, the 110 kDa protein secreted by *Shigella flexneri*: two-domain structure and proteolytic activity. *Microbiol* 144: 1815-1822.
51. Ben-Neriah Y. 2002. Regulatory functions of ubiquitination in the immune system. *Nat Immunol* 3: 20-26.
52. Bennish ML., Harris JR., Wojtyniak BJ., Struelens M. 1990. Death in shigellosis: incidence and risk factors in hospitalized patients. *J Infect Dis* 160: 500-506.
53. Bennish ML., Salam MA., Hossain MA., Myaux J., Khan EH., Chakraborty J., Henry F., Ronsmans C. 1992. Antimicrobial resistance of *Shigella* isolates in Bangladesh 1983-1990 increasing frequency of strains multiply resistant to ampicillin, cotrimoxazole and Nalidixic acid. *Clin Infect Dis* 14: 1055-1060.
54. Bergstrom KSB., Kisson-Singh V., Gibson DL., Ma CX., Montero M., Sham HP., Ryz N., Huang TN., Velcich A., Finlay BB., Chadee K., Vallance BA. 2010. Muc2 protects against lethal infectious colitis by disassociating pathogenic and commensal bacteria from the colonic mucosa. *Plos Pathogens* 6: 1-25.
55. Bernardeau M., Guguen M., Vernoux JP. 2006. Beneficial lactobacilli in food and feed: long-term use, biodiversity and proposals for specific and realistic safety assessments. *FEMS Microbiol Rev* 30 (4): 487-513.
56. Bernardini ML., Mounier J., Dhauteville H., Coquisrondon M., Sansonetti PJ. 1989. Identification of icsA, a plasmid locus of *Shigella flexneri* that governs bacterial intracellular and intercellular spread through interaction with F-actin. *Proc Natl Acad Sci* 86: 3867-3871.
57. Bernet MF., Brassart D., Neeser JR., Servin AL. 1994. *Lactobacillus acidophilus* LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. *Gut* 35 (4): 483-489.
58. Bernet MF., Lievin V., Brassart D., Neeser JR., Servin AL., Hudault S. 1997. The human *Lactobacillus acidophilus* strain LA1 secretes a nonbacteriocin antibacterial substance(s) active *in vitro* and *in vivo*. *Appl Environ Microbiol* 63: 2747-2753.

59. Bertani T., Abbate M., Zoia C., Coma D., Perico N., Ghezzi P., Remuzzi G. 1989. Tumor necrosis factor induces glomerular damage in rabbits. *Am J Pathol* 134: 419-430.
60. Betoret N., Puente L., Diaz MJ., Pagan MJ., Garcia MJ., Gras ML., Martinez-Monzo J., Fito P. 2003. Development of probiotic enriched dried fruits by vacuum impregnation. *J Food Eng* 56: 273-277.
61. Bhadoria PBS., Mahapatra SC. 2011. Prospects, technological aspects and limitations of probiotics – a worldwide review. *Eur J Food Res Rev* 1 (2): 23-42.
62. Bhattacharya SK., Dutta P., Dutta D., Bhattacharya MK., Sen D., Saha MR., Nair GB., Das P., Sikdar SN., Bose R., Pal SC. 1987. Relative efficacy of trimethoprim-sulfamethoxazole and nalidixic acid for acute invasive diarrhoea. *Antimicrob Agent Chemother* 31 (5): 675-837.
63. Bhattacharya SK., Bhattacharya MK., Dutta P., Sen D., Rasaily R., Moitra A., Pal SC. 1991. Randomized clinical trial of norfloxacin for shigellosis. *Am J Trop Med Hyg* 45: 683-687.
64. Bhattacharya MK., Nair GB., Sen D., Paul M., Debnath A., Nag A., Dutta D., Dutta P., Pal SC., Bhattacharya SK. 1992. Efficacy of norfloxacin for shigellosis: A double-blind randomized clinical trial. *J Diarrhoeal Dis Res* 10: 146-150.
65. Bhattacharya SK., Sur D. 2003. An evaluation of current shigellosis treatment. *Expert Opin Pharmacoth* 4 (8): 1315-1320.
66. Bhattacharya D., Sugunam AP., Bhattacharjee H., Thamizhmani R., Sayi DS., Thanasekaran K., Manimunda SP., Ghosh AR., Bharadwaj AP., Singhanian M., Roy S. 2012. Antimicrobial resistance in *Shigella*-rapid increase and widening of spectrum in Andaman islands, India. *Indian J Med Res* 135: 365-370.
67. Bibiloni R., Fedorak RN., Tannock GW., Madsen KL., Gionchetti P., Campieri M., De Simone C., Sartor RB. 2005. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. *Am J Gastroenterol* 100 (7): 1539-1546.
68. Bien J., Palagani V., Bozko P. 2013. The intestinal microbiota dysbiosis and *Clostridium difficile* infection: is there a relationship with inflammatory bowel disease? *Therap Adv Gastroenterol* 6 (1): 53-68.
69. Bierbaum G., Sahl HG. 2009. Lantibiotics: Mode of action, biosynthesis and bioengineering. *Curr Pharm Biotechnol* 10: 2-18.
70. Biet F., Loch C., Kremer L. 2002. Immunoregulatory functions of interleukin 18 and its role in defense against bacterial pathogens. *J Mol Med* 80 (3): 147-162.

71. Bilsborough J., Viney JL. 2004. Gastrointestinal dendritic cells play a role in immunity, tolerance, and disease. *Gastroenterol* 127: 300-309.
72. Bitzan M., Te Loo DM. 2003. Interaction of Shiga toxin with endothelial cells. *Methods Mol Med* 73: 243-262.
73. Blobel GC., Schiemann WP., Lodish HF. 2000. Role of transforming growth factor beta in human disease. *N Engl J Med* 342 (18): 1350-1358.
74. Blocker A., Jouihri N., Larquet E., Gounon P., Ebel F., Parsot C., Sansonetti P., Allaoui A. 2001. Structure and composition of the *Shigella flexneri* 'needle complex', a part of its type III secretion. *Mol Microbiol* 39: 652-663.
75. Borchers Q., Selmi C., Meyers F., Keen CL., Gershwin ME. 2009. Probiotics and immunity. *J Gastroenterol* 44: 26-46.
76. Borrueal N., Carol M., Casellas F., Antolín M., de Lara F., Espín E., Naval J., Guamer F., Malagelada JR. 2002. Increased mucosal tumour necrosis factor a production in Crohn's disease can be downregulated *ex vivo* by probiotic bacteria. *Gut* 51 (5): 659-664.
77. Bose R., Nashipuri JN., Sen PK., Dutta P., Bhattacharya SK., Dutta D., Sen D., Bhattacharya MK. 1984. Epidemic of dysentery in West Bengal: clinician's enigma. *Lancet* 2: 1160.
78. Bowler RP., Nicks M., Tran K., Tanner G., Chang LY., Young SK., Worthen GS. 2004. Extracellular superoxide dismutase attenuates lipopolysaccharide- induced neutrophilic inflammation. *Am J Respir Cell Mol Biol* 31: 432-439.
79. Braat H., de Jong EC., Van den Brande JM., Kapsenberg ML., Peppelenbosch MP., Van Tol EA., Van Deventer SJ. 2004. Dichotomy between *Lactobacillus rhamnosus* and *Klebsiella pneumoniae* on dendritic cell phenotype and function. *J Mol Med* 82: 197-205.
80. Braat H., Rottiers P., Hommes DW., Huyghebaert N., Remaut E., Remon JP., van Deventer SJ., Neiryck S., Peppelenbosch MP., Steidler L. 2006. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. *Clin Gastroenterol Hepatol* 4 (6): 754-759.
81. Bradford MM. 1976. A rapid and sensitive for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 72: 248-254.
82. Brat DJ., Bellail AC., Van Meir EG. 2005. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. *Neuro Oncol* 7 (2): 122-133.

83. Brisbin JT., Gong J., Parvizi P., Sharif S. 2010. Effects of Lactobacilli on Cytokine Expression by Chicken Spleen and Cecal Tonsil Cells. *Clin Vaccine Immunol* 17 (9): 1337-1343.
84. Bromberg Y., Pick E. 1980. Cyclic GMP metabolism in macrophages.1.regulation of cyclic GMP levels by Calcium and stimulation of cyclic GMP synthesis by NO-generating agents. *Cell Immunol* 62: 73-83
85. Brown AC., Valiere A. 2004. Probiotics and medical nutrition therapy. *Nutr Clin Care* 7 (2): 56–68.
86. Buchrieser C., Glaser P., Rusniok C., Nedjari H., D’Hauteville H., Kunst F., Sansonetti P., Parsot C. 2000. The virulence plasmid pWR100 and the repertoire of proteins secreted by the type III secretion apparatus of *Shigella flexneri*. *Mol Microbiol* 38: 760-771.
87. Byun R., Nadkarni MA., Chhour KL., Martin FE., Jacques NA., Hunter N. 2004. Quantitative analysis of diverse *Lactobacillus* species present in advanced dental caries. *J Clin Microbiol* 42 (7): 3128-3136.
88. Caballero-Franco C., Keller K., Simone CD., Chadee K. 2007. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. *American J Physiol Gastroint Liver Physiol* 292: 315-322.
89. Cakır I. 2003. Determination of some probiotic properties on *Lactobacilli* and *Bifidobacteria*. Ankara University Thesis of Ph.D, Ankara University, Turkey.
90. Camussi G., Bussolino F., Salvidio G., Baglioni C. 1987. Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and saccular endothelial cells to synthesize and release platelet activating factor. *J Exp Med* 166: 1390-1404.
91. Candela M., Maccaferri S., Turrone S. 2010. Functional intestinal microbiome, new frontiers in prebiotic design. *Int J Food Microbiol* 140: 93-101.
92. Cario E., Rosenberg IM., Brandwein SL., Beck PL., Reinecker HC., Podolsky DK. 2000. Lipopolysaccharide activates distinct signalling pathways in intestinal epithelial cell lines expressing Toll like receptors. *J Immunol* 164: 966-972.
93. Cario E., Brown D., McKee M., Lynch-Devaney K., Gerken G., Podolsky DK. 2002. Commensal-associated molecular patterns induce selective toll-like receptor-trafficking from apical membrane to cytoplasmic compartments in polarized intestinal epithelium. *Am J Pathol* 160 (1): 165-173.

94. Carlet J. 2012. The gut is the epicentre of antibiotic resistance. *Antimicrob Resist Infect Control* 1: 39-45.
95. Celli J., Finlay BB. 2002. Bacterial avoidance of phagocytosis. *Trends Microbiol* 10: 232-237.
96. Cervantes JL., Weinerman B., Basole C., Salazar JC. 2012. TLR8: the forgotten relative reindicated. *Cellular Mol Immunol* 9: 434-438.
97. Chanana C., Majumdar S., Rishi P. 2006. Tumour necrosis factor α mediated apoptosis in murine macrophages by *Salmonella enterica* serovar typhi under oxidative stress. *FEMS Immunol Med Microbiol* 47: 278-86.
98. Chanana V., Ray P., Rishi DB., Rishi P. 2007. Reactive nitrogen intermediates and monokines induce caspase-3 mediated macrophage apoptosis by anaerobically stressed *Salmonella typhi*. *Clin Exp Immunol* 150 (2): 368-374.
99. Chao CC., Hu S., Ehrlich L., Peterson PK. 1995. Interleukin-1 and tumor necrosis factor α synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-D-aspartate receptors. *Brain Behav Immun* 9: 355-365.
100. Charteris WP., Kelly PM., Morelli L., Collins JK. 1998. Antibiotic susceptibility of potentially probiotic *Lactobacillus* species. *J Food Prot* 61 (12): 1636-1643.
101. Chateau N., Deschamps AM., Hadj-Sassi, A. 1994. Heterogeneity of bile salts resistance in the *Lactobacillus* isolates from a probiotics consortium. *Lett Appl Microbiol* 18: 42-44.
102. Chatterjee BD. 1985. The so called epidemic of *Shigelladysenteriae* in West Bengal. *Trop Gastroenterol* 61: 69-83.
103. Chaudhary VP. 1983. Acute renal failure following bacillary dysentery-possible mechanisms of its pathogenesis. *Ind J Pediat* 50: 9-15.
104. Chauviere G., Coconnier MH., Kerneis S., Fourniat J., Servin AL. 1992. Adhesion of *Lactobacillus acidophilus* strain LB to human enterocyte-like Caco-2 cells. *J Gen Microbiol* 138: 1689-1696.
105. Chen CC., Louie S., Shi HN., Walker WA. 2005. Preinoculation with the probiotic *Lactobacillus acidophilus* early in life effectively inhibits murine *Citrobacter rodentium* colitis. *Pediatr Res* 58: 1185-1191.
106. Chen H., Hoover DG. 2003. Bacteriocins and their food applications. *Compr Rev Food Sci Food Saf* 2: 82-100.
107. Chen X., Xu J., Shuai J., Chen J., Zhang Z., Fang W. 2007. The S-layer proteins of *Lactobacillus crispatus* strain ZJ001 is responsible for competitive exclusion against

- Escherichia coli* O157:H7 and *Salmonella typhimurium*. Int J Food Microbiol 115: 307-312.
108. Chen Y., Smith MR., Thirumalai K., Zychlinsky A. 1996. A bacterial invasin induces macrophage apoptosis by directly binding. Ice Embo J 15: 3853-3860.
 109. Cherla RP., Lee SY., Tesh VL. 2003. Shiga toxins and apoptosis. FEMS Microbiol Lett 228: 159-166.
 110. Chichlowaski M., Croom J., McBride BW., Havenstein GB., Koci MD. 2007. Metabolic and physiological impact of probiotics or direct-fed-microbials on poultry: A brief review of current knowledge. Int J Poultry Sci 6: 694-704.
 111. Chieppa M., Rescigno M., Huang AY., Germain RN. 2006. Dynamic imaging of dendritic cell extension into the small bowel lumen in response to epithelial cell TLR engagement. J Exp Med 203: 2841-2852.
 112. Chiu YH., Lu YC., Ou CC., Lin SL., Tsai CC., Huang CT., Lin MY. 2013. *Lactobacillus plantarum* MYL26 induces endotoxin tolerance phenotype in Caco-2 cells. BMC Microbiol 13: 190-199.
 113. Chou LS., Weimer B. 1999. Isolation and characterization of acid- and bile-tolerant isolates from strains of *Lactobacillus acidophilus*. J Dairy Sci 82: 23-31.
 114. Christensen HR., Frokiaer H., Pestka JJ. 2002. *Lactobacilli* differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol 168: 171-178.
 115. Christopher PRH., David KV., John SM., Sankarapandian V. 2010. Antibiotic therapy for *Shigella dysenteriae* (Review). The Cochrane Library Issue 8.
 116. Chuang L., Wu KG., Pai C., Hsieh PS., Tsai JJ., Yen JH., Lin MY. 2007. Heat-killed cells of lactobacilli skew the immune response toward T helper 1 polarization in mouse splenocytes and dendritic cell-treated T cells. J Agric Food Chem 55 (26): 11080-11086.
 117. Chung YW., Choi JH., Oh TY, Eun CS., Han DS. 2008. *Lactobacillus casei* prevents the development of dextran sulphate sodium-induced colitis in Toll-like receptor 4 mutant mice. Clin Exp Immunol 151 (1): 182-189.
 118. Clerc PL., Ryter A., Mounier J., Sansonetti PJ. 1987. Plasmid mediated early killing of eukaryotic cells by *Shigella flexnerias* studied by infection of J774 macrophages. Infect Immun 55: 521-527.
 119. Coconnier MH., Bernet MF., Kern´eis S., Chauvi`ere G., Fourniat J., Servin AL. 1993. Inhibition of adhesion of enteroinvasive pathogens to human intestinal Caco-2 cells by

- Lactobacillus acidophilus* strain LB decreases bacterial invasion. FEMS Microbiol Lett 110 (3): 299-305.
120. Coconnier MH., Lievin V., Bernet-Camard MF., Hudault S., Servin AL. 1997. Antibacterial effect of the adhering human *Lactobacillus acidophilus* strain LB. Antimicrob Agents Chemother 41: 1046-1052.
 121. Coconnier MH., Lievin V., Lorrot M., Servin AL. 2000. Antagonistic activity of *Lactobacillus acidophilus* LB against intracellular *Salmonella enterica* serovar Typhimurium infecting human enterocyte-like Caco-2/TC-7 cells. Appl Environ Microbiol 66: 1152-1157.
 122. Collado MC., Gueimonde M., Sanz Y., Salminen S. 2006. Adhesion properties and competitive pathogen exclusion ability of Bifidobacteria with acquired acid resistance. J Food Prot 69 (7): 1675-1679.
 123. Collado MC., Meriluoto J., Salminen S. 2007. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. Lett Appl Microbiol 45: 454-460.
 124. Collins JW., La Ragione RM., Woodward MJ., Searle LEG. 2009. Application of Prebiotics and Probiotics in Livestock. In: Prebiotics and probiotics science and technology, Springer Science+Business Media B.V, New York, NY, USA, 1123-1192.
 125. Conradi H. 1903. Uber losliche, durch aseptische autolyse erhaltene giftstoffe von ruhrund typhus bazillen. Dtsch Med Wochenschr 20: 26-28.
 126. Conway PL., Gorbach SL., Goldin BR. 1987. Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. J Dairy Sci 70: 1-12.
 127. Cordes FS., Komoriya K., Larquet E., Yang SX., Egelman EH., Blocker A., Lea SM., 2003. Helical structure of the needle of the type III secretion system of *Shigella flexneri*. J Biol Chem 278: 17103-17107.
 128. Corr SC., Gahan CG., Hill C. 2007. Impact of selected *Lactobacillus* and *Bifidobacterium* species on *Listeria monocytogenes* infection and the mucosal immune response. FEMS Immunol Med Microbiol 50: 380-388.
 129. Cotter PD., Hill C., Ross RP. 2005. Bacteriocins: developing innate immunity for food. Nat Rev Microbiol 3: 777-788.
 130. D'Andrea A., Aste-Amezaga M., Valiante NM., Ma X., Kubin M., Trinchieri G. 1993. Interleukin 10 (IL-10) inhibits human lymphocyte interferon- γ production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 178: 1041-1048.

131. Daechel MA. 1989. Antimicrobial substances from lactic acid bacteria for use as food preservatives. *Food Technol* 43: 164-167.
132. Daeschel MA., Klaenhammer TR. 1985. Association of a 13.6-megadalton plasmid in *Pediococcus pentosaceus* with bacteriocin activity. *Appl Environ Microbiol* 50: 1538-1541.
133. Danielsen M. 2002. Characterization of the tetracycline resistance plasmid pMD5057 from *Lactobacillus plantarum* 5057 reveals a composite structure. *Plasmid* 48 (2): 98-103.
134. Dash A., Inman W., Holmaster K., Sevidal S., Kelly J., Obach RS., Griffith IG., Tannenbaum SR. 2009. Liver tissue engineering in the evaluation of drug safety. *Expert Opin Drug Metab Toxicol* 5: 1159-117.
135. De Leeuw E., Li X., Lu W. 2006. Binding characteristics of the *Lactobacillus brevis* ATCC 8287 surface layer to extracellular matrix proteins. *FEMS Microbiol Lett* 260: 210-215.
136. De Moreno de LeBlanc A., Matar C., Therriault C., Perdigon G. 2005. Effects of milk fermented by *Lactobacillus helveticus* R389 on immune cells associated to mammary glands in normal and a breast cancer model. *Immunobiol* 210: 349-358.
137. De Silva DGH., Mendis LN., Sheron N., Alexander GJM., Candy DCA., Chart H., Rowe B. 1993. Concentrations of interleukin 6 and tumour necrosis factor in serum and stools of children with *Shigella dysenteriae* 1 infection. *Gut* 34: 194-198.
138. De Silva DGH., Mendis LN., Sheron N., Alexander GJM., Candy DCA., Chart H., Rowe B. 1993. Concentrations of interleukin 6 and tumour necrosis factor in serum and stools of children with *Shigella dysenteriae* 1 infection. *Gut* 34: 194-198.
139. De Vuyst L., Leroy F. 2007. Bacteriocins from lactic acid bacteria: production, purification, and food applications. *J Mol Microbiol Biotechnol* 13: 194-199.
140. Dekruyi RH., Gieni RS., Umetsu DT. 1997. Antigen-driven but not lipopolysaccharide-driven IL-12 production in macrophages requires triggering of CD40. *J Immunol* 58: 359-366.
141. Del Piano M., Anderloni A., Balzarini M., Ballare M., Carmagnola S., Montino F., Orsello M., Pagliarulo M., Tari R., Soattini L., Sforza F., Mogna L., Mogna G. 2012. The innovative potential of *Lactobacillus rhamnosus* LR06, *Lactobacillus pentosus* LPS01, *Lactobacillus plantarum* LP01, and *Lactobacillus delbrueckii* Subsp. *delbrueckii* LDD01 to restore the "gastric barrier effect" in patients chronically treated with PPI: a pilot study. *J Clin Gastroenterol* 46: S18-S26.

142. DeLeo FR. 2004. Modulation of phagocyte apoptosis by bacterial pathogens. *Apoptosis* 9: 399-413.
143. Delgado A., Dulce B., Pedro F., Cidália P., Jose FM. 2001. Antimicrobial activity of *L. plantarum*, isolated from a traditional lactic acid fermentation of table olives. *Lait* 81: 203-215.
144. Demeria D., Ewaschuk J., Madsen K. 2009. Interactions of *Lactobacillus* with the Immune System. In *Lactobacillus* molecular biology: from genomics to probiotics, Caister Academic Press, Norfolk, UK, 139-152.
145. Denli M., Okan F., Elik CK. 2003. Effect of dietary probiotic, organic acid and antibiotic supplementation to diets on broiler performance and carcass yield. *Pakistan J Nutr* 2: 89-91.
146. Dhewa T., Bajpai V., Saxena RK., Pant S., Mishra V. 2010. Selection of *Lactobacillus* strains as potential probiotics on basis of *in vitro* attributes. *Int J Probiotics Prebiotics* 5 (1): 45-52.
147. Dickgiesser U., Weiss N., Fritsche D. 1984. *Lactobacillus gasseri* as the cause of septic urinary infection. *Infection* 12 (1): 14-16.
148. Dieleman LA., Goerres MS., Arends A., Sprengers D., Torrice C., Hoentjen F., Grenther W. B., Sartor RB. 2003. *Lactobacillus* GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. *Gut* 52: 370-376.
149. Dignass AK., Lynch-Devaney H., Kindon L., Thim L., Podolsky DK. 1994. Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway. *J Clin Invest* 94: 376-383.
150. Dinarello CA. 2007. A signal for the caspase-1 inflammasome free of TLR. *Immunity* 26: 383-385.
151. Dinarello CA., Mier JW. 1987. Lymphokines. *N Engl J Med* 317: 940-945.
152. Ding WK., Shah NP. 2009. An improved method of microencapsulation of probiotic bacteria for their stability in acidic and bile conditions during storage. *J Food Sci* 74: M53-M61.
153. Dobrindt U., Hochhut B., Hentschel U., Hacker J. 2004. Genomic islands in pathogenic and environmental microorganisms. *Nat Rev Microbiol* 2: 414-424.
154. Dotan I., Rachmilewitz D. 2005. Probiotics in inflammatory bowel disease: possible mechanisms of action. *Curr Opin Gastroenterol* 21: 426-430.

155. Drouault-Holowacz S., Bieuvelet S., Burckel A., Cazaubiel M., Dray X., Marteau P. 2008. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. *Gastroenterol Clin Biol* 32 (2): 147-152.
156. Drumm B., Neumann AW., Policova Z., Sherman PM. 1989. Bacterial cell surface hydrophobicity properties in the mediation of *in vitro* adhesion by the rabbit enteric pathogen *Escherichia coli* strain RDEC-1. *J Clin Invest* 84 (5): 1588-1549.
157. Du Toit M., Franz C., Schillinger U., Warles B., Holzappel W. 1998. Characterization and selection of probiotic lactobacilli for a preliminary minipig-feeding trail and their effect on serum cholesterol level, stool moisture contents. *Int J Food Microbiol* 40: 93-104.
158. Duary RK., Rajput YS., Batish VK., Grover S. 2011. Assessing the adhesion of putative indigenous probiotic lactobacilli to human colonic epithelial cells. *Indian J Med Res* 134: 664-671.
159. Duersteler M., Novak K., Davis E., Smith A., Rehberger T. 2010. Immunomodulatory effects of *Lactobacillus plantarum* and *Lactobacillus acidophilus* strains on a rat intestinal epithelial cell line. *J Immunol* 184: 137-121.
160. Dunne C., Murphy L., Flynn S., O'Mahony L., O'Halloran S., Feeney M., Morrissey D., Thornton G., Fitzgerald G., Daly C., Kiely B., Quigley EM., O'Sullivan GC., Shanahan F., Collins JK. 1999. Probiotics from myth to reality: Demonstration of functionality on animal models of disease and in human clinical trials. *Antonie Van Leeuwenhoek* 76: 279-292.
161. DuPont HL., Hornick RB., Dawkins AT., Snyder MJ., Formal SB. 1969. The response of man to virulent *Shigella flexneri* 2a. *J Infect Dis* 119: 296-299.
162. Dzidic S., Suskovic J., Kos B. 2008. Antibiotic resistance mechanisms in bacteria: Biochemical and genetic aspects. *Food Technol Biotechnol* 46: 11-21.
163. Edwards BH. 1999. *Salmonella* and *Shigella* species. *Clin Lab Med* 19: 469-487.
164. European Food Safety Authority. 2005. Opinion of the scientific committee on a request from EFSA related to a generic approach to the safety assessment by EFSA of microorganisms used in food/feed and the production of food/feed additives. *The EFSA Journal* 226: 1-12.
165. European Food Safety Authority. 2007. Introduction of a Qualified Presumption of Safety (QPS) approach for assessment of selected microorganisms referred to EFSA. *The EFSA Journal* 587: 1-16.

166. Elena G., Giovanna D., Brunella P., Anna D., Alessandro M., Maria T., Antonietta A. 2009. Proinflammatory signal transduction pathway induced by *Shigella flexneri* porins in Caco-2 cells. *Braz J Microbiol* 40: 701-709.
167. Elewaut D., DiDonato JA., Kim JM., Truong F., Eckmann L., Kagnoff MF. 1999. NF-kappa B is a central regulator of the intestinal epithelial cell innate immune response induced by infection with enteroinvasive bacterial. *J Immunol* 163: 1457-1466.
168. Emerenini EC., Afolabi OR., Okolie PI., Akintokun AK. 2014. *In vitro* studies on antimicrobial activities of lactic acid bacteria isolated from fresh vegetables for biocontrol of tomato pathogens. *Br Microbiol Res J* 4 (3): 351-359.
169. Ennahar S., Dechamps N., Richard J. 2000. Natural variation in susceptibility of *Listeria* strains to class IIa bacteriocins. *Curr Microbiol* 41: 1-4.
170. Esterbauer H., Schauer RJ., Zollner H. 1991. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. *Free Radic Biol Med* 11: 81-128.
171. Ewing WH. 1949. *Shigella* nomenclature. *J Bacteriol* 57: 633-638.
172. Ezendam J., Loveren H. 2006. Probiotics: immunomodulation and evaluation of safety and efficacy. *Nutr Rev* 64: 1-14.
173. Farfan MJ., Toro CS., Barry EM., Nataro JP. 2011. *Shigella* enterotoxin-2 is a type III effector that participates in *Shigella*-induced interleukin 8 secretions by epithelial cells. *FEMS Immunol Medical Microbiol* 61: 332-339.
174. Faruque AS., Teka T., Fuchs GJ. 1998. Shigellosis in children: a clinico-epidemiological comparison between *Shigella dysenteriae* type I and *Shigella flexneri*. *Ann Trop Paediatr* 18: 197-201.
175. Fasano A., Noriega FR., Liao FM., Wang W., Levine MM. 1997. Effect of *Shigella* enterotoxin 1 (ShET1) on rabbit intestine *in vitro* and *in vivo*. *Gut* 40: 505-511.
176. Fattman CL., Schaefer LM., Oury TD. 2003. Extracellular superoxide dismutase in biology and medicine. *Free Radic Biol Med* 35: 236-256.
177. Fattman CL., Tan RJ., Tobolewski JM., Oury TD. 2006. Increased sensitivity to asbestos-induced lung injury in mice lacking extracellular superoxide dismutase. *Free Radic Biol Med* 40: 601-607.
178. Favaro-Trindade CS., Grosso CR. 2002. Microencapsulation of *L. acidophilus* La- 05 and *B. lactis* Bb-12 and evaluation of their survival at the pH values of the stomach and in bile. *J Microencapsul* 19: 485-494.

179. Fayol-Messaoudi D., Berger CN., Coconnier-Polter MH., Lievin-Le V., Moal., Servin AL. 2005. pH-, lactic acid- and non-lactic acid-dependent activities against *Salmonella enterica* serovar Typhimurium by probiotic strains of *Lactobacillus*. *Appl Environ Microbiol* 71: 6008-6013.
180. Fedorak RN., Gionchetti P., Campieri M., Madsen K., Isaacs K. 2003. VSL3 probiotic mixture induces remission in patients with active ulcerative colitis. *Gastroenterol* 124 (4): 377-380.
181. Fernandes CF., Shahani KM., Amer MA. 1987. Therapeutic role of dietary lactobacilli and lactobacilli-fermented dairy products. *FEMS Microbiol Rev* 46: 343-356.
182. Ferreccio C., Prado V., Ojeda A., Cayayazo M., Abrego P., Guers L., Levine MM. 1991. Epidemiologic patterns of acute diarrhoea and endemic *Shigella* infections in a poor periurban setting in Santiago, Chile. *Am J Epidemiol* 134: 614-627.
183. Finamore A., Roselli M., Britti MS., Merendino N., Mengheri E. 2012. *Lactobacillus rhamnosus* GG and *Bifidobacterium animalis* MB5 induce intestinal but not systemic antigen-specific hyporesponsiveness in ovalbumin-immunized rats. *J Nutr* 142: 375-381.
184. Fiorentino M., Levine M.M., Sztein M.B., Fasano A. 2014. Effect of wild-type *Shigella* species and attenuated *Shigella* vaccine candidates on small intestinal barrier function, antigen trafficking, and cytokine release. *Plos One* 9 (1): e85211.
185. Flexner S. 1900. On the etiology of tropical dysentery. *Bull Johns Hopkins Hosp* 11: 231-242.
186. Fogh J., Fogh JM., Orfeo T. 1977. One hundred and twentyseven cultured human tumor cell lines producing tumors in nude mice. *J National Cancer Institute* 59 (1): 221-226.
187. Foligne B., Nutten S., Grangette C., Dennin V., Goudercourt D., Poiret S., Dewulf J., Brassart D., Mercenier A., Pot B. 2007. Correlation between *in vitro* and *in vivo* immunomodulatory properties of lactic acid bacteria. *World J Gastroenterol* 13: 236-243.
188. Fong Y., Tracey KJ., Moldawer LL., Hesse DG., Manogue KB., Kenney JS., Lee AT., Kuo GC., Allison AC., Lowry SF., Cerami A. 1989. Antibodies to cachectin/tumour necrosis factor reduce interleukin-1 alpha and interleukin-6 appearance during lethal bacteremia. *Exp Med* 170: 1627-1633.
189. Fons M., Hege T., Ladire M., Raibaud P., Ducluzeau R., Maquin E. 1997. Isolation and characterization of a plasmid from *Lactobacillus fermentum* conferring erythromycin resistance. *Plasmid* 37 (3): 199-203.

190. Fontaine A., Arondel J., Sansonetti PJ. 1988. Role of Shiga toxin in the pathogenesis of bacillary dysentery, studied by using a tox2 mutant of *Shigella dysenteriae* 1. *Infect Immun* 56: 3099-3109.
191. Fooks L., Gibson G. 2002. Probiotics as modulator of gut flora. *Br J Nutr* 88 (1): S39-S49.
192. Fooladi AI., Hosseini HM., Nourani MR., Khani S., Alavian SM. 2012. Probiotic as a novel treatment strategy against liver disease. *Hepatitis Monthly* 13 (2): e7521.
193. Forestier C., De Champs C., Vatoux C., Joly B. 2001. Probiotic activities of *Lactobacillus casei rhamnosus*: *in vitro* adherence to intestinal cells and antimicrobial properties. *Res Microbiol* 152: 167-173.
194. Forssten SD., Sindelar CW., Ouwehand AC. 2011. Probiotics from an industrial perspective. *Anaerobe* 17: 410-413.
195. Forsythe P., Bienenstock J. 2010. Immunomodulation by commensal and probiotic bacteria. *Immunol Invest* 39: 429-448.
196. Foye OT., Huang I., Chiou CC., Walker WA., Ning H. 2012. Early administration of probiotic *Lactobacillus acidophilus* and/or prebiotic inulin attenuates pathogen-mediated intestinal inflammation and Smad 7 cell signaling. *FEMS Immunol Med Microbiol* 65 (3): 467-480.
197. Francavilla R., Miniello V., Magistà AN., Canio A., Bucci N., Gagliardi F., Lionetti., Castellaneta S., Polimeno L., Peccarisi L., Indrio F., Cavallo L. 2010. A randomized controlled trial of *Lactobacillus* GG in children with functional abdominal pain. *Pediatr* 10: 1545-1542.
198. Francois M., Le Cabec V., Dupont MA., Sansonetti PJ., Maridonneau-Parini I. 2000. Induction of necrosis in human neutrophils by *Shigella flexneri* requires type III secretion, IpaB and IpaC invasins, and actin polymerization. *Infect Immun* 68: 1289-1296.
199. Frece J., Kos B., Svetec IK., Zgaga Z., Mrsa V., Suskovic J. 2005. Importance of S-layer proteins in probiotic activity of *Lactobacillus acidophilus* M92. *J Appl Microbiol* 98: 285-292.
200. Frece J., Kos B., Svetec IV., Zgaga Z., Beganovic JB., Lebos A., Suskovic J. 2009. Synbiotic effect of *Lactobacillus helveticus* M92 and prebiotics on the intestinal microflora and immune system of mice. *J Dairy Res* 76: 98-104.
201. Frece J., Suskovic J., Kos B., Beganovic J. 2005. Immunomodulatory effect of probiotic strain *Lactobacillus acidophilus* M92 in Mice. In *Current studies of biotechnology* Vol

- IV: Biotechnology and Immuno-Modulatory Drugs, Medicinska naklada, Zagreb, Croatia 153-165.
202. Fuller R. 1989. Probiotics in man and animals. *J Appl Bacteriol* 66: 365-378.
203. Furrle E. 2005. Probiotics and allergy. *Proceed Nutr Soc* 64: 465-469.
204. Galdeano CM., de Leblanc Ade M., Carmuega E., Weill R., Perdigon G. 2009. Mechanisms involved in the immunostimulation by probiotic fermented milk. *J Dairy Res* 76: 446-454.
205. Galdiero M., Vitiello M., Sanzari E., D'Isanto M., Tortora A., Longanella A., Galdiero, S. 2002. Porins from *Salmonella enterica* serovar Typhimurium activate the transcription factors activating protein1 and NF-kappa B through the Raf-1-mitogen activated protein kinase cascade. *Infect Immun* 70: 558-568.
206. Gangarosa EJ., Perera DP., Mata LJ., Morris CM., Guzman G., Reller LB. 1970. Epidemic Shiga bacillus dysentery in Central America, II Epidemiologic studies in 1969. *J Infect Dis* 122: 181-190.
207. Gao F., Koenitzer JR., Tobolewski JM., Jiang D., Liang J., Noble PW., Oury TD. 2008. Extracellular superoxide dismutase inhibits inflammation by preventing oxidative fragmentation of hyaluronan. *J Biol Chem* 283: 6058-6066.
208. Gasser F. 1994. Safety of lactic acid bacteria and their occurrence in human clinical infections. *Bull Inst Pasteur* 92: 45-67.
209. Gauffin-Cano P., Perdigon G. 2003. Probiotics induce resistance to enteropathogens in a re-nourished mouse model. *J Dairy Res* 70: 440-443.
210. Gawronska A., Dziechciarz P., Horvath A., Szajewska H. 2007. A randomized double-blind placebo-controlled trial of *Lactobacillus* GG for abdominal pain disorders in children. *Aliment Pharmacol Ther* 25: 177-184.
211. Geertsema-Doornbusch GI., Van der Mei HC., Busscher HJ. 1993. Microbial cell surface hydrophobicity, the involvement of electrostatic interactions in microbial adhesion to hydrocarbons (MATH). *J Microbiol Methods* 18 (1): 61-68.
212. Gerritsen J., Smidt H., Rijkers GT., de Vos WM. 2011. Intestinal Microbiota in human health and disease: the impact of probiotics. *Genes Nutr* 6: 209-240.
213. Gevers D., Danielsen M., Huys G., Swings J. 2003. Molecular characterization of tet (M) genes in *Lactobacillus* isolates from different types of fermented dry sausage. *Appl Environ Microbiol* 69 (2): 1270-1275.

214. Gfeller KY., Roth M., Teuber M. 2003. Sequence and genetic organization of the 19.3-kb erythromycin and dalbapristin-resistance plasmid pLME300 from *Lactobacillus fermentum* ROT1. *Plasmid* 50 (3): 190-201.
215. Ghosh AR., Sehgal SC. 1996. Existing status of shigellosis in Andaman & Nicobar Islands. *Indian J Med Res* 103: 134-137.
216. Ghosh AR., Sehgal SC. 1998. *Shigella* infections among children in Andaman-an archipelago of tropical islands in Bay of Bengal. *Epidemiol Infect* 121: 43-48.
217. Ghosh AR., Sugunan AP., Sehgal SC., Bharadwaj AP. 2003. Emergence of Nalidixic acid-resistant *Shigella sonnei* in acute-diarrhoea patients on Andaman and Nicobar Islands, India. *Antimicrob Agents Chemother* 47: 1480-1483.
218. Gibson GR., Roberfroid MB. 1995. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. *J Nutr* 125 (6): 1401-1412.
219. Gill HS. 2003. Probiotics to enhance anti-infective defences in the gastrointestinal tract. *Best Pract Res Clin Gastroenterol* 17: 755-773.
220. Gilliland SE. 1968. Enzymatic determination of residual hydrogen peroxide in milk. *J Dairy Sci* 52 (3): 321-4.
221. Gilliland SE., Staley TE., Bush LJ. 1984. Importance of bile tolerance of *Lactobacillus acidophilus* used as dietary adjunct. *J Dairy Sci* 67: 3045-3051.
222. Gilliland SE., Walker DK. 1989. Factors to consider when selecting a culture of *Lactobacillus acidophilus* as a dietary adjunct to produce a hypocholesteremic effect in humans. *J Dairy Sci* 73: 905-911.
223. Girardin SE., Boneca IG., Carneiro LA., Antignac A., Jehanno M., Viala J., Tedin K., Taha MK., Labigne A., Zahringer U., Coyle AG., DiStefano PS., Bertin J., Sansonetti PJ., Philpott DJ. 2003. Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. *Sci* 300: 1584-1587.
224. Goldberg MB., Barzu O., Parsot C., Sansonetti PJ. 1993. Unipolar localization and ATPase activity of IcsA, a *Shigella flexneri* protein involved in intracellular movement. *Infect Agents Dis* 2: 210-211.
225. Goldin GR., Gorbach SL. 1992. Probiotics for Humans. In *Probiotics– The Scientific Basis*, R. Fuller (Ed.), Chapman and Hall, London, UK, 355-376.
226. Golowczyc MA., Mobili P., Garrote GL., Abraham AG., De Antoni GL. 2007. Protective action of *Lactobacillus kefir* carrying S-layer protein against *Salmonella enterica* serovar Enteridis. *Int J Food Microbiol* 118: 267-273.

227. Goodrich ME., McGee DW. 1998. Regulation of mucosal B cell immunoglobulin secretion by intestinal epithelial cell-derived cytokines. *Cytokine* 10: 948-955.
228. Gopal PK., Prasad J., Smart J., Gill H. 2001. *In vitro* adherence properties of *Lactobacillus rhamnosus* DR20 and *Bifidobacterium lactis* DR10 strains and their antagonistic activity against an enterotoxigenic *Escherichia coli*. *Int J Food Microbiol* 67: 207-216.
229. Gorbach SL. 1987. Bacterial diarrhoea and its treatment. *Lancet* 2: 1378-1382.
230. Gorbach SL., Chang TW., Goldin B. 1987. Successful treatment of relapsing *Clostridium difficile* colitis with *Lactobacillus* GG. *Lancet* 2: 1519.
231. Gorden J., Small PL. 1993. Acid resistance in enteric bacteria. *Infect Immun* 61: 364-367.
232. Goren A., Freier S., Passwell JH. 1992. Lethal toxic encephalopathy due to childhood shigellosis in a developed country. *Pediatr* 89: 1189-1193.
233. Gotcheva V., Hristozova E., Hristozova T., Guo M., Roshkova Z., Angelov A. 2002. Assessment of potential probiotic properties of lactic acid bacteria and yeast strains. *Food Biotechnol* 16 (3): 211-225.
234. Gotuzzo E., Oberhelman RA., Maguina C., Berry SG., Yi A., Guzman M., Ruiz R., Leon-Barua R., Sack RB. 1989. Comparison of single-dose treatment with norfloxacin and standard 5-day treatment with trimethoprim sulphamethoxazole for acute shigellosis in adults. *Antimicrob Agents Chemother* 33: 1101-1104.
235. Green DH., Wakeley PR., Page A., Barnes A., Baccigalupi L., Ricca E., Cutting SM. 1999. Characterization of two *Bacillus* probiotics. *Appl Environ Microbiol* 65 (9): 4288-4291.
236. Greene JD., Klaenhammer TR. 1994. Factors involved in adherence of lactobacilli to human Caco-2 cells. *Appl Environ Microbiol* 60 (12): 4487-4494.
237. Gronbach K., Eberle U., Müller M., Olschläger TA., Dobrindt U., Leithäuser F., Niess JH., Döring G., Reimann J., Autenrieth IB., Frick JS. 2010. Safety of probiotic *Escherichia coli* strain Nissle 1917 depends on intestinal microbiota and adaptive immunity of the host. *Infect Immun* 78 (7): 3036-3046.
238. Gueimonde M., Noriega L., Margolles A., de los Reyes-Gavilan AC., Salminen S. 2005. Ability of *Bifidobacterium* strains with acquired resistance to bile to adhere to human intestinal mucus. *Int J Food Microbiol* 101: 341-346.
239. Gueimonde M., Sanchez B., de Los Reyes CG., Margolles A. 2013. Antibiotic resistance in probiotic bacteria. *Front Microbiol* 4: 202-208.

240. Guglielmetti S., Mora D., Gschwender M., Popp K. 2011. Randomised clinical trial: *Bifidobacterium bifidum* MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life—a double-blind, placebocontrolled study. *Aliment Pharmacol Ther* 33 (10): 1123-1132.
241. Gupta P., Andrew H., Kirschner BS., Guandalini S. 2000. Is *Lactobacillus* GG helpful in children with Crohn's disease? results of a preliminary, openlabel study. *J Pediatr Gastroenterol Nutr* 31 (4): 453-457.
242. Guslandi M., Giollo P., Testoni PA. 2003. A pilot trial of *Saccharomyces boulardii* in ulcerative colitis. *Eur J GastroenterolHepatol* 15 (6): 697-698.
243. Haest C., Kramp WMD., Deuliker B. 1977. Intra and intermolecular crosslinking membrane proteins in intact erythrocytes and ghosts by-SH oxidising agents. *Biochim Biophys Acta* 469: 226-230.
244. Haller D., Bode C., Hammes WP., Pfeifer AMA., Schiffrin EJ., Blum S. 2000. Non pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leukocyte co-cultures. *Gut* 47: 79-87.
245. Haller D., Holt L., Parlesak A., Zanga J., Bauerlein A. 2004. Differential effect of immune cells on non-pathogenic Gram-negative bacteria-induced nuclear factor-kappaB activation and pro-inflammatory gene expression in intestinal epithelial cells. *Immunol* 112: 310-20.
246. Hamilton-Miller JM. 2003. The role of probiotics in the treatment and prevention of *Helicobacter pylori* infection. *Int J Antimicrob Agents* 22 (4): 360-366.
247. Hampson DJ. 1994. Postweaning *Escherichia coli* diarrhoea in pigs. *Escherichia coli in Domestic Animals and Humans*, CAB International, Wallingford, UK, 171-191.
248. Harata G., He F., Kawase M., Hosono A., Takahashi K., Kaminogawa S. 2009. Differentiated implication of *Lactobacillus* GG and *L. gasseri* TMC0356 to immune responses of murine peyer's patch. *Microbiol Immunol* 53 (8): 475-480.
249. Harzallah D., Belhadj H. 2013. Lactic acid bacteria as probiotics: characteristics, selection criteria and role in immunomodulation of human GI mucosal barrier. *Lactic Acid Bacteria - R & D for Food, Health and Livestock Purposes*.
250. Hathaway LJ., Griffin GE., Sansonetti PJ., Edgeworth JD. 2002. Human monocytes kill *Shigella flexneri* but then die by apoptosis associated with suppression of proinflammatory cytokine production. *Infect Immun* 70: 3833-3842.
251. Havenaar R., Huis in't Veld JHJ. 1992. Probiotics: a general view. *The lactic acid bacteria in health and disease*, Elsevier, London, 151-170.

252. Helin T., Haahtela S., Haahtela T. 2002. No effect of oral treatment with an intestinal bacterial strain, *Lactobacillus rhamnosus* (ATCC 53103), on birchpollen allergy: a placebo-controlled double-blind study. *Allergy* 57: 243-246.
253. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., Horiuchi T., Tomizawa H., Takeda K., Akira S. 2002. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signalling pathway. *Nat Immunol* 3: 196-200.
254. Hempel S., Newberry SJ., Maher AR., Wang Z., Miles JN., Shanman R., Johnsen B., Shekelle PG. 2012. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. *JAMA* 307 (18): 1959-1969.
255. Hibbs JB., Taintor RR., Vavrin Z., Rachlin EM. 1988. Nitric oxide: a cytotoxic activated macrophages effector molecule. *Biochem Biophys Res Commun* 67: 87-94.
256. Hickey RM., Twommey DP., Ross RP., Hill C. 2003. Production of enterolysin A by a raw milk enterococcal isolate exhibiting multiple virulence factors. *Microbiol* 149: 655-664.
257. Hidalgo IJ., Raub TJ., Borchardt RT. 1989. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. *Gastroenterol* 96: 736-749.
258. Hilbi H., Chen Y., Thirumalai K., Zychlinsky A. 1997. The interleukin-1 α converting enzyme, caspase-1, is activated during *Shigella flexneri* induced apoptosis in human monocyte-derived macrophages. *Infect Immun* 65: 5165-5170.
259. Hilbi H., Moss JE., Hersh D., Chen Y., Arondel J., Banerjee S., Flavell RA., Yuan J., Sansonetti PJ., Zychlinsky A. 1998. *Shigella*-induced apoptosis is dependent on caspase-1 which binds to IpaB. *J Biol Chem* 273: 32895-32900.
260. Hirose K., Terajima J., Izumiya H., Tamura K., Arakawa E., Takai N., Watanabe H. 2005. Antimicrobial susceptibility of *Shigella sonnei* isolates in Japan and molecular analysis of *S. sonnei* isolates with reduced susceptibility to fluoroquinolones. *Antimicrob Agents Chemother* 49: 1203-1205.
261. Hoffman FA., Heimbach JT., Sanders ME., Hibberd PL. 2008. Executive summary: scientific and regulatory challenges of development of probiotics as foods and drugs. *Clin Infect Dis* 46 (2): 53-57.
262. Holzapfel WH., Haberer P., Snel J., Schillinger U., Huis in't Veld JHJ. 1998. Overview of gut flora and probiotics. *Int J Food Microbiol* 41: 85-101.

263. Hong KS., Hyoun Woo Kang HW., Im JP., Ji GE., Kim SG., Jung HC., Song IS., Kim JS. 2009. Effect of probiotics on symptoms in Korean adults with irritable bowel syndrome. *Gut Liver* 3 (2): 101-107.
264. Hood SK., Zottola EA. 1988. Effects of low pH on the ability of *Lactobacillus acidophilus* to survive and adhere to human intestinal cell. *J Food Sci* 53: 1514-1516.
265. Hoque SS., Faruque AS., Mahalanabis D., Hasnat A. 1994. Infectious agents causing acute watery diarrhoea in infants and young children in Bangladesh and their public implications. *J Trop Pediatr* 40: 351-354.
266. Hormansperger G., Haller D. 2010. Molecular crosstalk of probiotic bacteria with the intestinal immune system: clinical relevance in the context of inflammatory bowel disease. *Int J Med Microbiol* 300: 63-73.
267. Howard JG. 1955. Observations on the intoxication produced in mice and rabbits by the neurotoxin of *Shigella*. *Br J Exp Pathol* 36: 439-446.
268. Hsu DH., Moore K., Spits H. 1992. Differential effects of IL-4 and IL-10 on IL-2-induced IFN- γ synthesis and lymphokine-activated killer activity. *Int Immunol* 4 (5): 563-569.
269. Huang FC., Werne A., Li Q., Galyov EE., Walker WA., Cherayil BJ. 2004. Cooperative interactions between flagellin and SopE2 in the epithelial interleukin-8 response to *Salmonella enterica* serovar *typhimurium* infection. *Infect Immun* 72: 5052-5062.
270. Hudault S., Lievin V., Bernet-Camard MF., Servin AL. 1997. Antagonistic activity exerted *in vitro* and *in vivo* by *Lactobacillus casei* (strain GG) against *Salmonella typhimurium* C5 infection. *Appl Environ Microbiol* 63: 513-518.
271. Hugh R., Leifson E. 1953. The taxonomic significance of fermentative versus oxidative metabolism of carbohydrates by various Gram negative rods. *J Bacteriol* 66: 24-26.
272. Huys G., D'Haene K., Swings J. 2006. Genetic basis of tetracycline and minocycline resistance in potentially probiotic *Lactobacillus plantarum* strain CCUG 43738. *Antimicrob Agents Chemother* 50 (4): 1550-1551.
273. Ibnou-Zekri N., Blum S., Schiffrin EJ., Von der Weid T. 2003. Divergent patterns of colonization and immune response elicited from two intestinal *Lactobacillus* strains that display similar properties *in vitro*. *Infect Immun* 71: 428-436.
274. Imaoka A., Shima T., Kato K., Mizuno S., Uehara T., Matsumoto S., Setoyama H., Hara T., Umesaki Y. 2008. Anti-inflammatory activity of probiotic *Bifidobacterium*: enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative

- colitis patients and inhibition of IL-8 secretion in HT-29 cells. *World J Gastroenterol* 14 (16): 2511-2516.
275. Ingersoll MA., Zychlinsky A. 2006. ShiA abrogates the innate T-cell response to *Shigella flexneri* infection. *Infect Immun* 74: 2317-2327.
276. Ingrassia I., Leplingard A., Michaud AD. 2005. *Lactobacillus casei* DN-114 001 inhibits the ability of adherent-invasive *Escherichia coli* isolated from Crohn's disease patients to adhere to and to invade intestinal epithelial cells. *Appl Environ Microbiol* 71: 2880-2887.
277. Ingrassia I., Leplingard A., Michaud AD. 2005. *Lactobacillus casei* DN-114 001 inhibits the ability of adherent-invasive *Escherichia coli* isolated from Crohn's disease patients to adhere to and to invade intestinal epithelial Cells. *Appl Environ Microbiol* 71 (6): 2880-2888.
278. Islam MM, Azad AK, Bardhan PK, Raqib R, Islam D. 1994. Pathology of shigellosis and its complications. *Histopathology* 24 (1): 65-71.
279. Islam D., Wretling B., Lindberg AA., Christensson B. 1996. Changes in the peripheral blood T-cell receptor V beta repertoire *in vivo* and *in vitro* during shigellosis. *Infect Immun* 64: 1391-1399.
280. Islam D., Christensson B. 2000. Disease-dependent changes in T-cell populations in patients with shigellosis. *Apmis* 108: 251-260.
281. Islam D., Bandholtz L., Nilsson J., Wigzell H., Christensson B., Agerberth B., Gudmundsson G. 2001. Downregulation of bactericidal peptides in enteric infections: a novel immune escape mechanism with bacterial DNA as a potential regulator. *Nat Med* 7: 180-185.
282. Isolauri E., Sutas Y., Kankaanpaa P., Arvilommi H., Salminen S. 2001. Probiotics: Effects on immunity. *Am J Clin Nutr* 73 (2): 444-450.
283. Isolauri E. 2004. Dietary modification of atopic disease: use of probiotics in the prevention of atopic dermatitis. *Curr Allergy Asthma Rep* 4 (4): 27027-27035.
284. Isolauri E., Salminen S., Ouwenhand AC. 2004. Microbial-gut interactions in health and disease, probiotics. *Best Practice Res Clin Gastroenterol* 18 (2): 299-313.
285. Iyengar R., Stuehr DJ., Marletta MA. 1987. Macrophage synthesis of nitrite, nitrate, and N-nitrosamines: precursors and role of the respiratory burst. *Proc Natl Acad Sci USA* 84: 6369-6373.
286. Jacobsen CN., Rosenfeldt Nielsen V., Hayford AE., Moller PL., Michaelsen KF., Paerregaard A., Sandstrom B., Tvede M., Jakobsen M. 1999. Screening of probiotic

- activities of forty-seven strains of *Lactobacillus* spp by *in vitro* techniques and evaluation of the colonization ability of five selected strains in humans. *Appl Environ Microbiol* 65: 4949-4956.
287. Janeway CA., Medzhitov R. 2002. Innate immune recognition. *Annu Rev Immunol* 20: 197-216.
288. Jankowska A., Laubitz D., Antushevich H., Zabielski R., Grzesiuk E. 2008. Competition of *Lactobacillus paracasei* with *Salmonella enterica* for adhesion to Caco-2 Cells. *J Biomedicine Biotechnol*, Article ID 357964.
289. Jarlier V., Nicolas MH., Fournier G., Philippon A. 1988. The extended broad-spectrum β -lactamases confer a transferable resistance to the newer β -lactam agents in the Enterobacteriaceae: the hospital prevalence and the susceptibility patterns. *Rev Infect Dis* 10: 867-878.
290. Jenkins B., Holsten S., Bengmark S., Martindale R. 2005. Probiotics: a practical review of their role in specific clinical scenarios. *Nutr Clin Pract* 20: 262-270.
291. Jeong K., Zhang Q., Nunnari J., Tzinori S. 2010. A piglet model of acute gastroenteritis induced by *Shigella dysenteriae* type 1. *J Infect Dis* 201 (6): 903-911.
292. Jijon H., Backer J., Diaz H., Yeung H., Thiel D., McKaigney C., De Simone C., Madsen K. 2004. DNA from probiotic bacteria modulates murine and human epithelial and immune function. *Gastroenterol* 126: 1358-1373.
293. Jin LZ., Marquardt RR., Zhao X. 2000. A strain of *Enterococcus faecium* (18C23) inhibits adhesion of enterotoxigenic *Escherichia coli* K88 to porcine small intestine mucus. *Appl Environ Microbiol* 66: 4200-4204.
294. Jin Q., Yuan Z., Xu J., Wang Y., Shen Y., Lu W., Wang J., Liu H., Yang J., Yang F., Zhang X., Zhang J., Yang G., Wu H., Qu D., Dong J., Sun L., Xue Y., Zhao A., Gao Y., Zhu Y., Kan B., Ding K., Chen S., Cheng H., Yao Z., He B., Chen R., Ma D., Qiang B., Wen Y., Hou Y., Yu J. 2002. Genomesequence of *Shigella flexneri*2a: insights into pathogenicity through comparison with genomes of *Escherichia coli* K12 and O157. *Nucleic Acids Res* 30: 4432-4441.
295. Jin H., Higashikawa F., Noda M., Zhao X., Matoba Y., Kumagai T., Sugiyama M. 2010. Establishment of an *in vitro* Peyer's patch cell culture system correlative to *in vivo* study using intestine and screening of lactic acid bacteria enhancing intestinal immunity. *Biol Pharm Bull* 33 (2): 289-293.
296. Jobin C., Sartor RB. 2000. NF-kappaB signaling proteins as therapeutic targets for inflammatory bowel diseases. *Inflamm Bowel Dis* 6: 206-213.

297. Johnson LD., Jameson SC. 2009. Immunology-a chronic need for IL-21. *Sci* 324 (5934): 1525-1526.
298. Jollow D., Mitchell L., Zampaglione N., Gillete J. 1974. Bromobenzene induced liver necrosis: protective role of glutathione and evidence for 3, 4-bromobenzeneoxide as the hepatotoxic intermediate. *Pharmacol* 11: 151-169.
299. Jones SA. 2005. Directing transition from innate to acquired immunity: defining a role for IL-6. *J Immunol* 175 (6): 3463-3468.
300. Jung HC., Eckman L., Yang SK., Panja A., Fierer J., Morzycka-Wroblewska E., Kagnoff MF. 1995. A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. *J Clin Invest* 95 (1): 55-65
301. Jyoti B., Suresh AK., Venkatesh KV. 2003. Diacetyl production and growth of *Lactobacillus rhamnosus* on multiple substrates. *World J Microbiol Biotechnol* 19: 509-515.
302. Kailaspathy K., Chin J. 2000. Survival and therapeutic potential of probiotics organism with reference to *Lactobacillus acidophilus* and *Bifidobacterium* spp. *Immunol Cell Bio* 78: 80-88.
303. Kaisho T., Akira S. 2001. Dendritic-cell function in Toll-like receptor and MyD88-knockout mice. *Trends Immunol* 22: 78-83.
304. Kalliomaki M., Salminen S., Poussa T., Arvilommi H., Isolauri E. 2003. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. *Lancet* 361 (9372): 1869-1871.
305. Kamada N., Maeda K., Inoue N., Hisamatsu T., Okamoto S., Hong KS., Yamada T., Watanabe N., Tsuchimoto K., Ogata H., Hibi T. 2008. Nonpathogenic *Escherichia coli* strain Nissle 1917 inhibits signal transduction in intestinal epithelial cells. *Infect Immun* 76: 214-220.
306. Karin M., Ben-Neriah Y. 2000. Phosphorylation meets ubiquitination: the control of NFkappaB activity. *Ann Rev Immunol* 18: 621-627.
307. Kaser T., Gerner W., Mair K., Hammer SE., Patzl M., Saalmuller A. 2012. Current knowledge on porcine regulatory T cells. *Vet Immunol Immunopathol* 148: 136-138.
308. Kashket ER. 1987. Bioenergetics of lactic acid bacteria: cytoplasmic pH and osmotolerance. *FEMS Microbiol Rev* 46: 233-244.

309. Kaushik JK., Kumar A., Duary RK., Mohanty AK., Grover S., Batish VK. 2009. Functional and probiotic attributes of an indigenous isolate of *Lactobacillus plantarum*. PLoS One 4 (12): e11.
310. Kehrl JH. 1991. Transforming growth factor- β : an important mediator of immunoregulation. Int J Cell Cloning 9: 438-450.
311. Kelesidis T. 2012. Efficacy and safety of the probiotic *Saccharomyces boulardii* for the prevention and therapy of gastrointestinal disorders. Therap Adv Gastroenterol 5 (2): 111-125.
312. Kelly D., Conway S. 2005. Bacterial modulation of mucosal innate immunity. Mol Immunol 42: 895-901.
313. Khan WA., Dhar U., Salam MA., Griffiths JK., Rand W., Bennish ML. 1999. Central nervous system manifestations of childhood shigellosis: prevalence, risk factors and outcome. Pediatr 103: e18-26.
314. Khan SH., Ansari FA. 2007. Probiotics-the friendly bacteria with market potential in global market. Pak J Pharm Sci 20 (1): 76-82.
315. Ki MR., Ghim SY., Hong IH., Park JK., Hong KS., Ji AR., Jeong KS. 2010. *In vitro* inhibition of *Helicobacter pylori* growth and of adherence of cagA-positive strains to gastric epithelial cells by *Lactobacillus paraplantarum* KNUC25 isolated from kimchi. J Med Food 13 (3): 629-634.
316. Kim DW., Lenzen G., Page AL., Legrain P., Sansonetti PG., Parsot C. 2005. The *Shigella flexneri* effector OspG interferes with innate immune responses by targeting ubiquitin-conjugating enzymes. Proc Natl Acad Sci USA 102: 14046-14051.
317. Kim Y., Jeong Y., Kim A., Son H., Lee J., Jung C., Kim C., Kim J. 2014. *Lactobacillus brevis* strains from fermented aloe vera survive gastroduodenal environment and suppress common food borne enteropathogens. Plos One 9 (3): e90866.
318. Kindon H., Pothoulakis C., Thim L., Lynch-Devaney K., Podolsky DK. 1995. Trefoil peptide protection of intestinal epithelial barrier function: cooperative interaction with mucin glycoprotein. Gastroenterol 109: 516-523.
319. Kirschnek S., Scheffel J., Heinzmann U., Hacker G. 2004. Necrosis like cell death induced by bacteria in mouse macrophages. Eur J Immunol 34: 1461-1471.
320. Kitazawa H., Tohno M., Shimosato T., Saito T. 2008. Development of molecular immunoassay system for probiotics via Toll-like receptors based on food immunology. Animal Sci J 79: 11-21

321. Kitazawa H., Villena J. 2014. Modulation of respiratory TLR3- antiviral response by probiotic microorganisms: lessons learned from *Lactobacillus rhamnosus* CRL1505. *Front Immunol* 5: 201-216.
322. Klaenhammer TR. 1988. Bacteriocins of lactic acid bacteria. *Biochemie* 70: 337-349.
323. Klaenhammer TR. 1993. Genetics of bacteriocins produced by lactic acid bacteria. *FEMS Microbiol Rev* 12: 39-85.
324. Klaenhammer TR., Kullen MJ. 1999. Selection and design of probiotics. *Int J Food Microbiol* 50 (1): 45-57.
325. Klein C., Entian KD. 1994. Genes involved in self-protection against the lantibiotic subtilin produced by *Bacillus subtilis* ATCC 6633. *Appl Environ Microbiol* 60: 2793-2801.
326. Klimpel GR., Shaban R., Niesel DW. 1990. Bacteria infected fibroblasts have enhanced susceptibility to the cytotoxic action of tumor necrosis factor. *J Immunol* 145: 711-717.
327. Klingberg TD., Budde BB. 2006. The survival and persistence in the human gastrointestinal tract of five potential probiotic lactobacilli consumed as freeze-dried cultures or as probiotic sausage. *Int J Food Microbiol* 109 (1-2): 157-159.
328. Ko JS., Yang HR., Chang JY., Seo JK. 2007. *Lactobacillus plantarum* inhibits epithelial barrier dysfunction and interleukin-8 secretion induced by tumor necrosis factor- α . *World J Gastroenterol* 13 (13): 1962-1965.
329. Koga T., Mizobe T., Takumi K. 1998. Antibacterial activity of *Lactobacillus* species against *Vibrio* species. *Microbiol Res* 153: 271-275.
330. Kohler H., Rodrigues SP., McCormick BA. 2002. *Shigella flexneri* interactions with the basolateral membrane domain of polarized model intestinal epithelium: role of lipopolysaccharide in cell invasion and in activation of the mitogen-activated protein kinase ERK. *Infect Immun* 70: 1150-1158.
331. Kojima H., Yanai Y., Nagaoka K., Takeuchi M., Ohta T., Ikegami H., Ikeda M., Kurimoto M. 1999. An essential role for NF-kappaB in IL-18-induced IFN-gamma expression in KG-1 cells. *J Immunol* 162: 5063-5069.
332. Konkel JE., Chen W. 2011. Balancing acts: the role of TGF-beta in the mucosal immune system. *Trends Mol Med* 17: 668-676.
333. Kono Y. 1978. Generation of superoxide radical during auto-oxidation of hydroxylamine and on assay for superoxide dismutase. *Arch Biochem Biophys* 186: 189-195.

334. Kopp MV., Hennemuth I., Heinzmann A., Urbanek R. 2008. Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of *Lactobacillus* GG supplementation. *Pediatr* 121 (4): 850-856.
335. Kos B., Suskovic J., Beganovic J., Gjuracic K., Frece J., Iannaccone C., Canganella F. 2008. Characterization of the three selected probiotic strains for the application in food industry. *World J Microbiol Biotechnol* 24: 699-707.
336. Kosek M., Yori PP., Pan WK., Chavez CB., Sanchez GM., Burga R., Hall E. 2008. The epidemiology of the highly endemic, multiple antibiotic-resistant Shigellosis in children in the Peruvian Amazon. *Pediatr* 122 (3): e541-549.
337. Koster F., Levin J., Walker L., Tung KS., Gilman RH., Rahaman MM., Majid MM., Islam S., Williams RC. 1978. Hemolytic-uremic syndrome after shigellosis, relation to endotoxemia and circulating immune complexes. *N Eng J Med* 298: 927-933.
338. Kostrzynska M., Bachand A. 2006. Use of microbial antagonism to reduce pathogen levels on produce and meat products: a review. *Can J Microbiol* 52: 1017-1026.
339. Kotani Y., Kunisawa J., Suzuki Y., Sato I., Saito T., Toba M., Kohda N., Kiyono H. 2014. Role of *Lactobacillus pentosus* strain b240 and the toll-like receptor 2 axis in peyer's patch dendritic cell-mediated immunoglobulin enhancement. *Plos One* 9 (3): e91857.
340. Koterski JF., Nahvi M., Venkatesan MM., Haimovich B. 2005. Virulent *Shigella flexnerica* causes damage to mitochondria and triggers necrosis in infected human monocyte-derived macrophages. *Infect Immun* 73: 504-513.
341. Kotloff KL., Winickoff JP., Ivanoff B., Clemens JD., SwerdlowDL., Sansonetti PJ., Adak GK., Levine MM. 1999. Global burden of *Shigella* infections: implications for vaccine development and implementation of control strategies. *Bull World Health Org* 77: 651-66.
342. Kotzamanidis C., Kourelis A., Litopoulou-Tzanetaki E., Tzanetaki N., Yiangou M. 2010. Evaluation of adhesion capacity, cell surface traits and immunomodulatory activity of presumptive probiotic *Lactobacillus* strains. *Int J Food Microbiol* 140: 154-163.
343. Kozakova D., Holubova J., Plockova M., Chumchalova J., Curda L. 2005. Impedance measurement of growth of lactic acid bacteria in the presence of nisin and lysozyme. *European Food Res Technol* 221: 774-778.
344. Krieg AM., Davis HL. 2001 Enhancing vaccines with immune stimulatory CpG DNA. *Curr Opin Mol Ther* 3: 15-24.

345. Kuleasan H., Cakmakci ML. 2002. Effect of reuterin produced by *Lactobacillus reuteri* on the surface of sausages to inhibit the growth of *Listeria monocytogenes* and *Salmonella* spp. *Nahrung Food* 46: 408-410.
346. Kumagai T., Matsukawa N., Kaneko Y., Kusumi Y., Mitsumata M., Uchida K. 2004. A lipid peroxidation-derived inflammatory mediator identification of 4-hydroxy-2-nonenal as a potential inducer of cyclooxygenase-2 in macrophages. *J Biological Chem* 279 (46): 48389-48396.
347. Kumar M., Verma V., Nagpal R. 2011. Effect of probiotic fermented milk and chlorophyllin on gene expressions and genotoxicity during AFB1-induced hepatocellular carcinoma. *Gene* 490 (2): 54-59.
348. Kweon MN. 2008. Shigellosis: the current status of vaccine development. *Curr Opin Infect Dis* 21: 313-318.
349. Lan A., Lagadic-Gossmann D., Lemaire C. 2007. Acidic extracellular pH shifts colorectal cancer cell death from apoptosis to necrosis upon exposure to propionate and acetate, major end-products of the human probiotic *Propionibacteria*. *Apoptosis* 12: 573-591.
350. Land MH., Rouster-Stevens K., Woods CR., Cannon ML., Cnota J., Shetty AK. 2005. *Lactobacillus* sepsis associated with probiotic therapy. *Pediatr* 115 (1): 178-181.
351. Laohachai KN., Bahadi R., Hardo MB., Hardo PG., Kourie JJ. 2003. The role of bacterial and non-bacterial toxins in the induction of changes in membrane transport: implications for diarrhea. *Toxicon* 42: 687-707.
352. Le Gall T., Mavris M., Martino MC., Bernardini ML., Denamur E., Parsot C. 2005. Analysis of virulence plasmid gene expression defines three classes of effectors in the type III secretion system of *Shigella flexneri*. *Microbiol* 151: 951-962.
353. Le-Barillec K., Magalhaes JG., Corcuff E., Thuizat A., Sansonetti PJ., Phalipon A., Di Santo JP. 2005. Roles for T and NK cells in the innate immune response to *Shigella flexneri*. *J Immunol* 175: 1735-1740.
354. Lebeer S., Vanderleyden J., De Keersmaecker SC. 2008. Genes and molecules of lactobacilli supporting probiotic action. *Microbiol Mol Biol Rev* 72: 728-764.
355. Lee YK., Puong KY. 2002. Competition for adhesion between probiotics and human gastrointestinal pathogens in the presence of carbohydrate. *Br J Nutr* 88 (Suppl. 1): S101-S108.

356. Lee YK., Puong KY., Arthur C., Ouwehand A., Salminen S. 2003. Displacement of bacterial pathogens from mucus and Caco-2 cell surface by lactobacilli. *J Med Microbiol* 52: 925-930.
357. Lee KH., Park JY., Jeong SJ., Kwon GH., Lee HJ., Chang HC., Chung DK., Lee JH., Kim JH. 2007. Characterization of paraplantaricin C7, a novel bacteriocin produced by *Lactobacillus paraplantarum* C7 isolated from kimchi. *J Microbiol Biotechnol* 17 (2): 286-296.
358. Lee SK., Kok K., Jaume M., Cheung TKW., Yip T., Lai JCC., Guan Y., Webster RG., Jin DY., Peiris JSM. 2014. Toll-like receptor 10 is involved in induction of innate immune responses to influenza virus infection. *PNAS* 111 (10): 3793-3798.
359. Lehto EM., Salminen SJ. 1997. Inhibition of *Salmonella typhimurium* adhesion to Caco-2 cell cultures by *Lactobacillus* strain GG spent culture supernate: only a pH effect? *FEMS Immunol Med Microbiol* 18: 125-132.
360. Leroy F., Verluypen J., De Vuyst L. 2006. Functional meat starter cultures for improved sausage fermentation. *Int J Food Microbiol* 106: 270-285
361. Lett MC., Sasakawa C., Okada N., Sakai T., Makino S., Yamada M., Komatsu K., Yoshikawa M. 1989. VirG, a plasmid-coded virulence gene of *Shigella flexneri*: identification of the VirG protein and determination of the complete coding sequence. *J Bacteriol* 171: 353-359.
362. Letterio JJ., Roberts AB. 1998. Regulation of immune responses by TGF-beta. *Annu Rev Immunol* 16: 137-161.
363. Letterio JJ. 2005. TGF-beta signaling in T cells: roles in lymphoid and epithelial neoplasia. *Oncogene* 24: 5701-5712.
364. Levine MM., DuPont HL., Formal SB., Hornick RB., Takeuchi A., Gangarosa EJ., Snyder MJ., Libonati JP. 1973. Pathogenesis of *Shigella dysenteriae* 1 (Shiga) dysentery. *J Infect Dis* 127: 261-270.
365. Levine MM. 1991. Shigellosis. In: Strickland GT, Hunters tropical medicine-7th Edition, WB Saunders and company, Philadelphia, 340-344.
366. Levine M., Kotloff KL., Barry EM., Pasetti MF., Sztein MB. 2007. Clinical trials of *Shigella* vaccines: two steps forward and one step back on a long, hard road. *Nat Rev Microbiol* 5: 540-553.
367. Levy J. 2000. The effects of antibiotic use on gastrointestinal function. *Am J Gastroenterol* 95: 8-10.

368. Li Q., Verma IM. 2002. NF-kappaB regulation in the immune system. *Nat Rev Immunol* 2: 725-734.
369. Li CY., Lin HC., Lai CH., Lu JJ., Wu SF., Fang SH. 2011. Immunomodulatory effects of *Lactobacillus* and *Bifidobacterium* on both murine and human mitogen-activated T cells. *Int Arch Allergy Immunol* 156 (2): 128-136.
370. Li XQ., Zhu YH., Zhang HF., Yue Y., Cai ZX., Lu QP., Zhang L., Weng XG., Zhang FJ., Zhou D., Yang JC., Wang JF. 2012. Risks associated with high-dose *Lactobacillus rhamnosus* in an *Escherichia coli* model of piglet diarrhoea: intestinal microbiota and immune imbalances. *PLoS One* 7: e40666.
371. Lievin-Le Moal V., Servin AL. 2006. The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota. *Clin Microbiol Rev* 19 (2): 315-337.
372. Lilly DM., Stillwell RH. 1965. Growth promoting factors produced by microorganisms. *Science* 147: 747-748.
373. Lin CF., Fung ZF., Wu CL., Chung TC. 1996. Molecular characterization of a plasmid-borne (pTC82) chloramphenicol resistance determinant (cat-TC) from *Lactobacillus reuteri* G4. *Plasmid* 36 (2): 116-124.
374. Lindgren SE., Dobrogosz WJ. 1990. Antagonistic activities of lactic acid bacteria in food and feed fermentations. *FEMS Microbiol Rev* 87:149-164.
375. Liong MT. 2008. Roles of probiotics and prebiotics in colon cancer prevention: postulated mechanisms and *in-vivo* evidence. *Int J Mol Sci* 9 (5): 854-863.
376. Liong MT., Shah NP. 2005. Bile salt deconjugation ability, bile salt hydrolase activity and cholesterol co-precipitation ability of lactobacillistrains. *Int Dairy J* 15 (4): 391-398.
377. Loenders B., Van Mechelen E., Nicolai S., Buysens N., Van Osselaer N., Jorens PG., Willems J., Herman AG., Slegers H. 1998. Localization of extracellular superoxide dismutase in rat lung: neutrophils and macrophages as carriers of the enzyme. *Free Radic Biol Med* 24: 1097-1106.
378. Loguercio C., Federico A., Tuccillo C., Terracciano F., D'Auria MV., De Simone C., Del Vecchio BC. 2005. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. *J Clin Gastroenterol* 39 (6): 540-543.
379. Longdet IY., Kutshik RJ., Nwoyeocha JG. 2011. The probiotic efficacy of *Lactobacillus casei* from human breast milk against shigellosis in albino rats. *Adv Biotechnol Chem Process* 1: 12-16.

380. Lorca GL., de Valdez GE. 2009. *Lactobacillus* stress responses. *Lactobacillus* molecular biology: from genomics to probiotics. Caister Academic Press Norfolk, UK, 115-138.
381. Lorea Baroja M., Kirjavainen PV., Hekmat S., Reid G. 2007. Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. *Clin Exp Immunol* 149: 470-479.
382. Lupp C., Finlay BB. 2005. Intestinal microbiota. *Curr Biol* 15: 235-236.
383. Luster AD. 2002. The role of chemokines in linking innate and adaptive immunity. *Curr Opin Immunol* 14: 129-135.
384. Ma D., Forsythe P., Bienenstock J. 2004. Live *Lactobacillus reuteri* is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression. *Infect Immun* 72: 5308-5314.
385. Maassen CB., Claassen E. 2008. Strain-dependent effects of probiotic lactobacilli on EAE autoimmunity. *Vaccine* 26 (17): 2056-2057.
386. Macdonald J., Galley HF., Webster NR. 2003. Oxidative stress and gene expression in sepsis. *Br J Anaesth* 90: 221-232.
387. MacFaddin JF. 1980. Biochemical tests for identification of medical bacteria. Lippincott Williams and Wilkins, Philadelphia, USA.
388. Mack DR., Ahrne S., Hyde L., Wei S., Hollingsworth MA. 2003. Extracellular MUC3 mucin secretion follows adherence of *Lactobacillus* strains to intestinal epithelial cells *in vitro*. *Gut* 52: 827-833.
389. Mackowiak PA. 2013. Recycling Metchnikoff probiotics, the intestinal microbiome and the quest for long life. *Front Public Health* 1: 52-55.
390. Madigan M., Martinko J. 2005. Brock Biology of Microorganisms (11th ed). Prentice Hall, New Jersey, USA.
391. Madsen K., Cornish A., Soper P., McKaigney C., Jijon H., Yachimec C., Doyle J., Jewell L., De Simone C. 2001. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. *Gastroenterol* 121: 580-591.
392. Magalhaes JG., Philpott DJ., Nahori MA., Jehanno M., Fritz J., Le Bourhis L., Viala J., Hugot JP., Giovannini M., Bertin J. 2005. Murine Nod1 but not its human orthologue mediates innate immune detection of tracheal cytotoxin. *EMBO Rep* 6: 1201-1207.
393. Mainville I., Arcand Y., Farnworth ER. 2005. A dynamic model that simulates the human upper gastrointestinal tract for the study of probiotics. *Int J Food Microbiol* 99 (3): 287-296.

394. Majamaa H., Isolauri E. 1997. Probiotics: a novel approach in the management of food allergy. *J Allergy Clin Immunol* 99 (2): 179-185.
395. Malin M., Suomalainen H., Saxelin M., Isolauri E. 1996. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with *Lactobacillus* GG. *Annals Nutr Metabol* 40 (3): 137-145.
396. Mandal J., Ganesh V., Emelda J., Mahadevan S., Parija SC. 2012. The recent trends of shigellosis: a JIPMER perspective. *J Clin Diagnostic Res* 6 (9): 1474-1477.
397. Mandal S. 2006. Microencapsulation of probiotics and their application in manufacture of biodynamic milk chocolate. Ph.D. Dissertation. NDRI Deemed University, Karnal, India.
398. Mandal V., Sen SK., Mandal NC. 2009. Effect of prebiotics on bacteriocin production and cholesterol lowering activity of *Pediococcus acidilactici* LAB 5. *World J Microbiol Biotechnol* 25: 1837-1841.
399. Mandal J., Mondal N., Mahadevan S., Parija SC. 2010. The emergence of resistance to the third generation cephalosporins in *Shigella*- A case report. *J Trop Paediatr* 56: 278-279.
400. Mangell P., Nejdfors P., Wang M., Ahrne S., Westrom B., Thorlacius H., Jeppsson B. 2002. *Lactobacillus plantarum* 299v inhibits *Escherichia coli*-induced intestinal permeability. *Dig Dis Sci* 47: 511-516.
401. Mapple LJ., Tchorzewska MA., Cooley WA., Woodward MJ., La Ragione RM. 2011. Lactobacilli antagonize the growth, motility, and adherence of *Brachyspira pilosicoli*: a potential intervention against avian intestinal spirochetosis. *Appl Environ Microbiol* 77 (15): 5402-5411.
402. Marks PA., Richon VM., Miller T. 2004. Histone deacetylase inhibitors. *Adv Cancer Res* 91: 137-168.
403. Marletta MA., Yoon PY., Iyengar R., Leaf CD., Wishnok JS. 1988. Macrophage oxidation of L-arginine to nitrite and nitrate: nitric oxide is an intermediate. *Biochem* 27: 8706-8711
404. Martea PR., de Vrese M., Cellier CJ., Schrezenmeir J. 2001. Protection from gastrointestinal diseases with the use of probiotics. *Am J Clin Nutr* 73: 430S-436S.
405. Marteau P., Flourie B., Pochart F., Chastang C., Desjeux JF., Rambaud JC. 1990. Effect of the microbial lactase (EC 3.2.1.23) activity in yoghurt on the intestinal absorption of lactose: an *in vivo* study in lactase-deficient humans. *Br J Nutr* 64: 71-79.

406. Martel A., Meulenaere V., Devriese L., Decostere A., Haesebrouck F. 2003. Macrolide and lincosamide resistance in the gram-positive nasal and tonsillar flora of pigs. *Microb Drug Resist* 9 (3): 293-297.
407. Massari P., Visintin A., Gunawardana J., Halmen KA., King CA., Golenbock DT., Wetzler LM. 2006. Meningococcal porin PorB binds to TLR2 and requires TLR1 for signaling. *J Immunol* 176: 2373-2380.
408. Mata LJ., Gangarosa EJ., Caceres A., Perera DR., Mejicanos ML. 1970. Epidemic Shiga bacillus dysentery in Central America. etiologic investigations in Guatemala, 1969. *J Infect Dis* 122: 170-180.
409. Matar C., Valdez JC., Medina M., Rachid M., Perdigon G. 2001. Immunomodulating effect of milks fermented by *Lactobacillus helveticus* and its non-proteolytic variant. *J Dairy Res* 68: 601-609.
410. Mathan VI., Mathan MM. 1991. Intestinal manifestations of invasive diarrhoeas and their diagnosis. *Rev Infect Dis* 13 (Suppl 4): 311-313.
411. Matsuzaki T., Takagi A., Ikemura H., Matsuguchi T., Yokokura T. 2007. Intestinal microflora: probiotics and autoimmunity. *J Nutr* 137(3 Suppl 2): 798S-802S.
412. Maudsdotter L., Jonsson H., Roos S., Jonsson AB. 2011. Lactobacilli reduce cell cytotoxicity caused by *Streptococcus pyogenes* by producing lactic acid that degrades the toxic component lipoteichoic acid. *Antimicrob Agents Chemother* 55 (5): 1622-1628.
413. Mavris M., Page AL., Tournebize R., Demers B., Sansonetti P., Parsot C. 2002. Regulation of transcription by the activity of the *Shigella flexneri* type III secretion apparatus. *Mol Microbiol* 43: 1543-1553.
414. Mayo B., Van S., Douwe. 2010. Bifidobacteria: genomics and molecular aspects. Caister Academic Press, Norfolk, England.
415. McCartney AL., Wenzhi W., Tannock GW. 1996. Molecular analysis of the composition of the bifidobacterial and *Lactobacillus* microflora of humans. *Appl Environ Microbiol* 62: 4608-4613.
416. McClemens J., Kim J., Wang H., Mao Y., Collins M., Kunze W., Bienenstock J., Forsythe P., Khan W. 2013. *Lactobacillus rhamnosus* ingestion promotes innate host defense in an enteric parasitic infection. *Clin Vaccine Immunol* 20 (6): 818-826.
417. Medzhitov R., Janeway CA. 1997. Innate immunity: the virtues of a nonclonal system of recognition. *Cell* 91: 295-298.

418. Metchnikoff E., Mitchell PC. 1910. The Prolongation of Life. Optimistic Studies. G P Putnam's Sons, New York.
419. Miller TL., McGee DW. 2002. Epithelial cells respond to proteolytic and non-proteolytic detachment by enhancing interleukin-6 responses. *Immunol* 105: 101-110.
420. Mimura T., Rizzello F., Helwig U., Poggioli G., Schreiber S., Talbot IC., Nicholls RJ., Gionchetti P., Campieri M., Kamm MA. 2004. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. *Gut* 53: 108-114.
421. Mishra V., Prasad DN. 2005. Application of in vitro methods for selection of *Lactobacillus casei* strains as potential probiotics. *Int J Food Microbiol* 103: 109-115.
422. Mital BK., Garg SK. 1995. Anticarcinogenic, hypocholesterolemic, and antagonistic activities of *Lactobacillus acidophilus*. *Critical Rev Microbiol* 21 (3): 174-214.
423. Mitsuoka T. 1992. The human gastrointestinal tract. In: The Lactic acid bacteria, Wood, Elsevier Applied Science, New York, 69-114.
424. Mocellin S., Panelli MC., Wang E., Nagorsen D., Marincola FM. 2004. The dual role of IL-10. *Trends Immunol* 24 (1): 36-43.
425. Mohankumar A. 2011. Characterization and Antibacterial Activity of Bacteriocin Producing *Lactobacillus* Isolated from Raw Cattle Milk Sample. *Int J Biology* 3 (3): 128-143.
426. Moore WEC., Holdeman LV. 1974. Human fecal flora: the normal flora of 20 Japanese- Hawaiians. *Appl Microbiol* 27: 961-979.
427. Moore KW., de Waal Malefyt R., Coffman RL., O'Garra A. 2001. Interleukin-10 and the interleukin-10 receptor. *Annu Rev Immunol* 19 (1): 683-765.
428. Moorthy G., Murali MR., Devaraj SN. 2007. Protective role of lactobacilli in *Shigella dysenteriae* 1-induced diarrhea in rats. *Nutr* 23: 424-433.
429. Moorthy G., Murali MR., Devaraj SN. 2010. Lactobacilli inhibit *Shigella dysenteriae* 1 induced pro-inflammatory response and cytotoxicity in host cells via impediment of *Shigella*-host interactions. *Dig Liver Dis* 42: 33-39.
430. Mor M., Yuhas Y., Kaminsky E., Dinari G., Ashkenazi S. 1996. Induction of tumor necrosis factor and nitric oxide by *Shigella* strains isolated from patients with or without neurologic manifestations. *Isr J Med Sci* 32: 1271-1275.
431. Morelli LC., Cesena C., de Haen., Gozzini L. 1998. Taxonomic *Lactobacillus* composition of feces from human newborns during the first few days. *Microb Ecol* 35: 205-212.

432. Morelli L. 2000. *In Vitro* selection of probiotic lactobacilli: a critical appraisal. *Curr Issues Intes Microbiol* 1 (2): 59-67.
433. Mourad K., Nour-Eddine K. 2006. *In vitro* preselection criteria for probiotic *Lactobacillus plantarum* strains of fermented olives origin. *Int J Probiotics Prebiotics* 1 (1): 27-32.
434. Muhialdin BJ., Hassan Z., Sadon S., Zulkifli NA., Azfar AA. 2011. Effect of pH and heat treatment on antifungal activity of *Lactobacillus fermentum* TE007, *Lactobacillus pentosus* G004 and *Pediococcus pentosaceus* TE010. *Innovat Rom Food Biotechnol* 8: 41-53.
435. Munshi MH., Sack DA., Halder K., Ahmed ZU., Rahaman MM., Murshed MO. 1987. Plasmid-mediated resistance to nalidixic acid in *Shigella dysenteriae* type 1. *Lancet* 2: 419-421.
436. Murphy G., Bodhidatta L., Echeverria P., Tansuphaswadikul S., Hoge CW., Imlarp S., Tamura K. 1993. Ciprofloxacin and loperamide in the treatment of bacillary dysentery. *Ann Intern Med* 118: 582-586.
437. Naheed A., Kalluri P., Talukder KA., Faruque AS., Khatun F., Nair GB., Nair GB., Mintz ED., Breiman RF. 2004. Fluoroquinolone-resistant *Shigella dysenteriae* type 1 in northeastern Bangladesh. *Lancet Infect Dis* 4: 607-608.
438. Naidu AS., Bidlack WR., Clemens RA. 1999. Probiotic Spectra of Lactic Acid Bacteria (LAB). *Critical Rev Food Sc Nutr* 38 (1): 13-126.
439. Nakata N., Sasakawa C., Okada N., Tobe T., Fukuda I., Suzuki T., Komatsu K., Yoshikawa M. 1992. Identification and characterization of virK, a virulence-associated large plasmid gene essential for intercellular spreading of *Shigella flexneri*. *Mol Microbiol* 6: 2387-2395.
440. Nandakumar NS., Pugazhendhi S., Ramakrishna BS. 2009. Effects of enteropathogenic bacteria & lactobacilli on chemokine secretion & Toll like receptor gene expression in two human colonic epithelial cell lines. *Indian J Med Res* 130: 170-178.
441. Nataro JP., Seriwatana J., Fasano A., Maneval DR., Guers LD., Noriega F., Dubovsky M., Levine M., Morris JG. 1995. Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive *Escherichia coli* and *Shigella* strains. *Infect Immun* 63: 4721-4728.
442. Nawaz M., Wang J., Zhou A., Ma C., Wu X., Xu J. 2011. Screening and characterization of new potentially probiotic lactobacilli from breast-fed healthy babies in Pakistan. *Afr J Microbiol Res* 5 (12): 1428-1436.

443. Nawroth PP., Stern DM. 1986. Modulation of endothelial cell haemostatic properties of tumor necrosis factor. *J Exp Med* 163: 740-745.
444. Nelson JD., Kusmiesz H., Jackson LH. 1976. Comparison of trimethoprim/sulphamethoxazole and ampicillin therapy for shigellosis in ambulatory patients. *J Pediatr* 89: 491-493
445. Nes IF., Diep DB., Havarstein LS., Brurberg MB. 1996. Biosynthesis of bacteriocins in lactic acid bacteria. *Antonie van Leeuwenhoek* 70: 113-128.
446. Nes IF., Johnsborg O. 2004. Exploration of antimicrobial potential in LAB by genomics. *Curr Opin Biotech* 15: 100-104.
447. Neutra M., Louvard D. 1989. Differentiation of intestinal cells *in vitro*. *Mol Cell Biol* 8: 363-398.
448. Ng KY., Griffiths MW. 2002. Enhancement of macrophage cytokine release by cell-free fractions of fermented milk. *Milchwissenschaft* 57: 66-70.
449. Ng EK., Panesar N., Longo WE., Shapiro MJ., Kaminski DL., Tolman KC., Mazuski JE. 2003. Human intestinal epithelial and smooth muscle cells are potent producers of IL-6. *Mediators Inflamm* 12: 3-8.
450. Ng SC., Hart AL., Kamm MA., Stagg AJ., Knight SC. 2009. Mechanisms of action of probiotics: recent advances. *Inflamm Bowel Dis* 15: 300-310.
451. Nicholls S., Stephens S., Braegger CP., Walker-Smith JA., MacDonald TT. 1993. Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. *J Clin Pathol* 46: 757-760.
452. Niedzielin K., Kordecki H., Birkenfeld B. 2001. A controlled, double-blind, randomized study on the efficacy of *Lactobacillus plantarum* 299V in patients with irritable bowel syndrome. *Eur J Gastroenterol Hepatol* 13 (10): 1143-1147.
453. Niers LE., Hoekstra MO., Timmerman HM., Van Uden NO., De Graaf PM., Smits HH., Kimpfen JL., Rijkers GT. 2007. Selection of probiotic bacteria for prevention of allergic diseases: immunomodulation of neonatal dendritic cells. *Clin Exp Immunol* 149: 344-352.
454. Niesel DW., Hess CB., Cho YJ., Klimpel KD., Klimpel GR. 1986. Natural and recombinant interferons inhibit epithelial cell invasion by *Shigella* spp. *Infect Immun* 52: 823-833.
455. Niku-Paavola ML., Laitila A., Mattila-Sandholm T., Haikara A. 1999. New types of antimicrobial compounds produced by *Lactobacillus plantarum*. *J Appl Microbiol* 86: 29-35.

456. Nilsen T., Nes IF., Holo H. 2003. Enterolysin A, a cell wall-degrading bacteriocin from *Enterococcus faecalis* LMG 2333. *Appl Environ Microbiol* 69: 2975-2984.
457. Niyogi SK., Mitra U., Dutta P. 2001. Changing pattern of serotypes and antimicrobial susceptibilities of *Shigella* species isolated from children in Calcutta, India. *Jpn J Infect Dis* 54: 121-122.
458. Niyogi SK., Pazhani GP. 2003. The multi-resistant *Shigella* species which were isolated from the childhood diarrhea cases in Kolkata, India. *Jpn J Infect Dis* 56: 33-34.
459. Niyogi SK. 2005. Shigellosis. *J Microbiol* 43: 133-143.
460. Nonaka Y., Izumo T., Izumi F., Maekawa T., Shibata H., Nakano A., Kishi A., Akatani K., Kiso Y. 2008. Antiallergic effects of *Lactobacillus pentosus* strain S-PT84 mediated by modulation of Th1/Th2 immunobalance and induction of IL-10 production. *Int Arch Allergy Immunol* 145: 249-257.
461. O'Flaherty S., Goh YJ., Klaenhammer TR. 2009. Genomics of probiotic bacteria. In: *prebiotics and probiotics science and technology*. Springer Science plus Business Media New York, NY, USA, 683-726.
462. O'Hara AM., O'Regan P., Fanning A., O'Mahony C., Macsharry J., Lyons A., Bienenstock J., O'Mahony L., Shanahan F. 2006. Functional modulation of human intestinal epithelial cell responses by *Bifidobacterium infantis* and *Lactobacillus salivarius*. *Immunol* 118: 202-215.
463. O'Hara AM., Shanahan F. 2007. Gut microbiota: Mining for therapeutic potential. *Clin Gastroenterol Hepatol* 5: 274-284.
464. O'Loughlin EV., Robins-Browne RM. 2001. Effect of Shiga toxin and Shiga-like toxins on eukaryotic cells. *Microbes Infect* 3: 493-507.
465. O'Mahony L., McCarthy J., Kelly P., Hurley G., Luo F., Chen K., O'Sullivan GC., Kiely B., Collins JK., Shanahan F., Quigley EM. 2005. *Lactobacillus* and *Bifidobacterium* in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. *Gastroenterol* 128: 541-551.
466. O'Sullivan GC., Kelly P., O'Halloran S., Collins C., Collins JK., Dunne C., Shanahan F. 2005. Probiotics: an emerging therapy. *Curr Pharm Des* 11: 3-10.
467. Ogawa M., Yoshimori T., Suzuki T., Sagara H., Mizushima N., Sasakawa C. 2004. Escape of intracellular *Shigella* from autophagy. *Sci* 307 (5710): 727-731.
468. Ohashi Y., Ushida K. 2009. Health-beneficial effects of probiotics: its mode of action. *Animal Sci J* 80 (4): 361-371.

469. Okud J., Toyotome T., Kataoka N., Ohno M., Abe H., Shimura Y., Seyedarabi A., Pickersgill R., Sasakawa C. 2005. *Shigella* effector IpaH9.8 binds to a splicing factor U2AF (35) to modulate host immune responses. *Biochem Biophys Res Commun* 333: 531-539.
470. Osawa R., Fujisawa T., Pukall R. 2006. *Lactobacillus apodami* sp. nov., a tannase producing species from wild mouse faeces. *Int J Sys Evol Microbiol* 56: 1693-1696
471. Oswald IP. 2006. Role of intestinal epithelial cells in the innate immune defence of the pig intestine. *Vet Res* 37: 359-368.
472. Otte JM., Cario E., Podolsky DK. 2004. Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. *Gastroenterol* 126: 1054-1070.
473. Ou CC., Lin SL., Tsai JJ., Lin MY. 2011. Heat-killed lactic acid bacteria enhance immunomodulatory potential by skewing the immune response toward Th1 polarization. *J Food Sci* 76 (5): M260-M267.
474. Ouwehand AC., Salminen S., Isolauri E. 2002. Probiotics: an overview of beneficial effects. *Antonie Van Leeuwenhoek* 82: 279-289.
475. Ouwehand AC., Saxelin M., Salminen S. 2004. Phenotypic differences between commercial *Lactobacillus rhamnosus* GG and *L. rhamnosus* strains recovered from blood. *Clin Infect Dis* 39 (12): 1858-1860.
476. Ouyang W., Rutz S., Crellin NK., Valdez PA., Hymowitz SG. 2011. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. *Annu Rev Immunol* 29: 71-109
477. Ozinsky A., Underhill DM., Fontenot JD., Hajjar AM., Smith KD., Wilson CB., Schroeder L., Aderem A. 2000. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. *Proc Natl Acad Sci USA* 97: 13766-13771.
478. Pal SC. 1984. Epidemic bacillary dysentery in West Bengal. *Lancet* 2: 1462.
479. Palmer RMJ., Ferrige DS., Moncada S. 1987. Nitric oxide release accounts for the biological activity of endothelium derived relaxing factor. *Nutr* 327: 524-526.
480. Pan W., Zadina JE., Harlan RE., Weber JT., Banks WA., Kastin AJ. 1997. Tumor necrosis factor α : a neuromodulator in the CNS. *Neurosci Biobehav Rev* 21: 603-613.
481. Panhotra BR., Desai B., Sharma PL. 1985. Nalidixic acid resistant *Shigella dysenteriae* type 1. *Lancet* 1: 763.

482. Parassol N., Freitas M., Thoreux K., Dalmasso G., Bourdet-Sicard R., Rampal P. 2005. *Lactobacillus casei* DN-114 001 inhibits the increase in paracellular permeability of enteropathogenic *Escherichia coli*-infected T84 cells. Res Microbiol 156: 256-262.
483. Parrish-Novak J., Dillon SR., Nelson A., Hammond A., Sprecher C., Gross JA., Johnston J., Madden K., Xu W., West J., Schrader S., Burkhead S., Heipel M., Brandt C., Kuijper JL., Kramer J., Conklin D., Presnell SR., Berry J., Shiota F., Bort S., Hambly K., Mudri S., Clegg C., Moore M., Grant FJ., Lofton-Day C., Gilbert T., Rayond F., Ching A., Yao L., Smith D., Webster P., Whitmore T., Maurer M., Kaushansky K., Holly RD., Foster D. 2000. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nutr 408 (6808): 57-63.
484. Parrish-Novak J., Foster DC., Holly RD., Clegg CH. 2002. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol 72 (5): 856-63.
485. Parsot C, Sansonetti PJ. 1996. Invasion and pathogenesis of *Shigella* infections. Curr Top Microbiol Immunol 209: 25-42.
486. Parsot C. 2005. *Shigella* spp. and enteroinvasive *Escherichia coli* pathogenicity factors. FEMS Microbiol Lett 252: 11-18.
487. Parvez S., Malik KA., Kang S., Kim HY. 2006. Probiotics and their fermented food products are beneficial for health. J Appl Microbiol 100 (6): 1171-1185.
488. Patel HM., Pandiella SS., Wang RH., Webb C. 2004. Influence of malt, wheat and barley extracts on the bile tolerance of selected strains of lactobacilli. Food Microbiol 21: 83-89.
489. Pazhani GP., Sarkar B., Ramamurthy T., Bhattacharya SK., Takeda Y., Niyogi SK. 2004. Clonal multidrug resistant *Shigella dysenteriae* type 1 strains associated with the epidemic and sporadic dysenteries in eastern India. Antimicrob Agents Chemother 48 (2): 681-684.
490. Pazhani GP., Niyogi SK., Singh AK., Sen B., Taneja N., Kundu M., Yamasaki S, Ramammurthy T. 2008. The molecular characterization of the multi-drug resistant *Shigella* spp which were isolated from the epidemic and the endemic cases of Shigellosis in India. J Med Microbiol 57 (7): 856-863.
491. Pedron T., Thibault C., Sansonetti PG. 2003. The invasive phenotype of *Shigella flexneri* directs a distinct gene expression pattern in the human intestinal epithelial cell line Caco-2. J Biol Chem 278: 33878-33886.

492. Pena JA., Rogers AB., Ge Z., Ng V., Li SY., Fox JG., Versalovic J. 2005. Probiotic *Lactobacillus* spp. diminish *Helicobacter hepaticus*-induced inflammatory bowel disease in interleukin-10-deficient mice. *Infect Immun* 73 (2): 912-920.
493. Peng S., Lin JY., Lin MY. 2007. Antiallergic effect of milk fermented with lactic acid bacteria in a murine animal model. *J Agric Food Chem* 55 (13): 5092-5096.
494. Perdigon G., De Macias MEN., Alvarez S., Oliver G., De Ruiz Holgado AA. 1986. Effect of perorally administered lactobacilli on macrophage activation in mice. *Infect Immun* 53 (2): 404-410.
495. Perdigon G., S. Alvarez, and A. Pesce de Ruiz Holgado. 1991. Immunoadjuvant activity of oral *Lactobacillus casei*: influence of dose on the secretory immune response and protective capacity in intestinal infections. *J Dairy Res* 58: 485-496.
496. Perdigon C., Maldonado-Galdeano A., De Moreno de LeBlanc CG., Vinderola M., Medici ME., Bibas Bonet. 2004. Immunomodulation of mucosal immune response by probiotics. *Curr Trends Immunol* 6: 69-85.
497. Pessi T., Sutas Y., Hurme M., Isolauri E. 2000. Interleukin-10 generation in atopic children following oral *Lactobacillus rhamnosus* GG. *Clin Exp Allergy* 30: 1804-1808.
498. Petersen SV., Oury TD., Ostergaard L., Valnickova Z., Wegrzyn J., Thogersen IB., Jacobsen C., Bowler RP., Fattman CL., Crapo JD., Enghild JJ. 2004. Extracellular superoxide dismutase (EC-SOD) binds to type I collagen and protects against oxidative fragmentation. *J Biol Chem* 279: 13705-13710.
499. Pfeffer K. 2003. Biological functions of tumor necrosis factor cytokines and their receptors. *Cytokine Growth Factor Rev* 14 (3-4): 185-191.
500. Phalipon A., Sansonetti PJ. 2003. Shigellosis: innate mechanisms of inflammatory destruction of the intestinal epithelium, adaptive immune response, and vaccine development. *Crit Rev Immunol* 23: 371-401.
501. Phalipon A., Sansonetti PJ. 2007. *Shigella*'s ways of manipulating the host intestinal innate and adaptive immune system: a tool box for survival? *Immunol Cell Biol* 85 (2): 119-129.
502. Philpott DJ., Yamaoka S., Israel A., Sansonetti PJ. 2000. Invasive *Shigella flexneri* activates NF-kappa B through a lipopolysaccharide-dependent innate intracellular response and leads to IL-8 expression in epithelial cells. *J Immunol* 165: 903-914.
503. Philpott DJ., Girardin SE., Sansonetti PJ. 2003. Innate immune responses of epithelial cells following infection with bacterial pathogens. *Curr Opin Immunol* 13: 410-416.

504. Philpott DJ., Girardin SE. 2004. The role of Toll-like receptors and Nod proteins in bacterial infection. *Mol Immunol* 41: 1099-1108.
505. Pignata S., Maggini L., Zarrilli R., Rea A., Acquaviva AM. 1994. The enterocyte like differentiation of the Caco-2 tumor cell line strongly correlates with responsiveness to cAMP and activation of kinase A pathway. *Cell Growth Differ* 5: 967-973.
506. Pithva S., Shekh S., Dave J., Vyas BR. 2014. Probiotic attributes of autochthonous *Lactobacillus rhamnosus* strains of human origin. *Appl Biochem Biotechnol* 173 (1): 259-277.
507. Podolsky SH. 2012. Metchnikoff and the microbiome. *Lancet* 380 (9856): 1810-1811.
508. Pridmore RD., Pittet AC., Praplan F., Cavadinin C. 2008. Hydrogen peroxide production by *Lactobacillus johnsonii* NCC533 and its role in anti-*Salmonella* activity. *FEMS Microbiol Lett* 283 (2): 210-215.
509. Puniya M., Sangu K., Bhardwaj A., Gupta D., Kumar S., Dhewar T., Pant S. 2012. Probiotic and functional attributes of *Lactobacillus* spp isolated from human faeces. *J Res Antimicrob* 1: 32-42.
510. Qamar A., Aboudola S., Warny M., Michetti P., Pothoulakis C., Lamont JT., Kelly CP. 2001. *Saccharomyces boulardii* stimulates intestinal immunoglobulin A immune response to *Clostridium difficile* toxin A in mice. *Infect Immun* 69: 2762-2765.
511. Rachmilewitz D., Karmeli F., Shteingart S., Lee J., Takabayashi K., Raz E. 2006. Immunostimulatory oligonucleotides inhibit colonic proinflammatory cytokine production in ulcerative colitis. *Inflamm Bowel Dis* 12: 339-345.
512. Rachmilewitz D., Katakura K., Karmeli F., Hayashi T., Reinus C., Rudensky B., Akira S., Takeda K., Lee J., Takabayashi K., Raz E. 2004. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. *Gastroenterol* 126: 520-528.
513. Radice M., Gonzalez C., Power P., Vidal MDC., Gutkind G. 2000. Third-generation cephalosporin resistance in *Shigella sonnei* in Argentina. *Emerg Infect Dis* 7: 1-2.
514. Radtke AL., O'Riordan MX. 2006. Intracellular innate resistance to bacterial pathogens. *Cell Microbiol* 8: 1720-1729.
515. Rafter J. 2004. The effects of probiotics on colon cancer development. *Nutr Res Rev* 17 (2): 277-284.
516. Rahaman MM., Khan MM., Aziz KMS., Islam MS., Kibriya AK. 1975. An outbreak of dysentery caused by *Shigella dysenteriae* type 1 on a coral island in the Bay of Bengal. *J Infect Dis* 132 (1): 15-19.

517. Raja SB., Murali MR., Devaraj H., Devaraj SN. 2011. Differential expression of gastric MUC5AC in colonic epithelial cells: TFF3-wired IL1b/Akt crosstalk-induced mucosal immune response against *Shigella dysenteriae* infection. *J Cell Sci* 125 (3): 702-713.
518. Rakoff-Nahoum S., Medzhitov R. 2006. Role of the innate immune system and host-commensal mutualism. *Curr Top Microbiol Immunol* 308: 1-18.
519. Ramegowda B., Samuel JE., Tesh VL. 1999. Interaction of shiga toxins with human brain microvascular endothelial cells: cytokines as sensitizing agents. *J Infect Dis* 180: 1205-1213.
520. Ramiah K., Van Reenena CA., Dicks LM. 2007. Expression of the mucus adhesion genes Mub and MapA, adhesion-like factor EF-Tu and bacteriocin gene plaA of *Lactobacillus plantarum* 423, monitored with real-time PCR. *Int J Food Microbiol* 116 (3): 405-409.
521. Raqib R., Lindberg AA., Wretling B., Bardhan PK., Andersson U., Andersson J. 1995. Persistence of local cytokine production in shigellosis in acute and convalescent stages. *Infect. Immun* 63: 289-296.
522. Raqib R., Gustafsson A., Andersson J., Bakhiet M. 1997. A systemic downregulation of gamma interferon production is associated with acute shigellosis. *Infect Immun* 65: 5338-5341.
523. Raqib R., Ekberg C., Sharkar P., Bardhan P K., Zychlinsky A., Sansonetti P J., Andersson J. 2002. Apoptosis in acute shigellosis is associated with increased production of Fas/Fas ligand, perforin, caspase-1, and caspase-3 but reduced production of Bcl-2 and interleukin1-B. *Infect Immun* 70 (6): 3199-3207.
524. Ray A., Biswas T. 2004. Porin of *Shigella dysenteriae* enhances Toll-like receptors 2 and 6 of mouse peritoneal B-2 cells and induces the expression of immunoglobulin M, immunoglobulin G2a and immunoglobulin A. *Immunol* 114: 94-100.
525. Raya RR., Klaenhammer TR. 1992. High-frequency plasmid transduction by *Lactobacillus gasseri* bacteriophage adh. *Appl Environ Microbiol* 58: 187-193.
526. Reddy B. 1998. Prevention of colon cancer by pre- and probiotics: evidence from laboratory studies. *Br J Nutr* 80: 219-223.
527. Reid G. 2008. Probiotic lactobacilli for urogenital health in women. *J Clin Gastroenterol* 42 (Suppl 3): 234-236.
528. Reiter RJ., Acuna-Castroviejo D., Tan DX., Burkhardt S. 2001. Free radical mediated molecular damage-mechanisms for the protective actions of melatonin in the central nervous system. *Ann NY Acad Sci* 939: 200-215.

529. Ren DY., Li C., Qin YQ., Yin RL., Du SW., Ye F., Liu HF., Wang MP., Sun Y., Li X., Tan MY., Jin NY. 2013. Lactobacilli reduce chemokine IL-8 production in response to TNF- α and *Salmonella* challenge of Caco-2 cells. *Bio Med Res Int*: 925219
530. Rennick DM, Fort MM. 2000. Lessons from genetically engineered animal models. XII, IL-10-deficient (IL-10(-/-) mice and intestinal inflammation. *Am J Physiol Gastrointest Liver Physiol* 278: G829-G833.
531. Resta-Lenert S., Barrett KE. 2003. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive *Escherichia coli* (EIEC). *Gut* 52: 988-997.
532. Rettger LF., Levy MN., Weinstein L., Weiss JE. 1935. *Lactobacillus acidophilus* and its therapeutic action. Yale University Press.
533. Rettig RJ., Nelson JD. 1982. *Shigella* infections. In Kelly VC (ed.): Practice of Pediatrics volume 4, Harper and Row Publishers, Philadelphia, 1-27.
534. Rimoldi M., Chieppa M., Larghi P., Vulcano M., Allavena P., Rescigno M. 2005. Monocyte-derived dendritic cells activated by bacteria or by bacteria-stimulated epithelial cells are functionally different. *Blood* 106: 2818-2826.
535. Rishi P., Mavi SK., Bharrhan S., Shukla G., Tewari R. 2009. Protective efficacy of probiotic alone or in conjugation with prebiotic in *Salmonella* induced liver damage. *FEMS Microbiol Ecol* 69: 222-30.
536. Rishi P., Preet S., Kaur P. 2011. Effect of *L. plantarum* cell-free extract and cotrimoxazole against *Salmonella Typhimurium*: a possible adjunct therapy. *Annal Clin Microbiol Antimicrob* 10: 9-17.
537. Rizzo A., Losacco A., Carratelli CR. 2013. *Lactobacillus crispatus* modulates epithelial cell defense against *Candida albicans* through Toll-like receptors 2 and 4, interleukin 8 and human β -defensins 2 and 3. *Immunol Lett* 156 (1-2): 102-109
538. Rodriguez H., De las Rivas B., Gomez-Cordoves C. 2008. Characterization of tannase activity in cell-free extracts of *Lactobacillus plantarum* CECT 748T. *Int J Food Microbiol* 121: 92-98.
539. Rogelj I., Bogovic-Matijasic B. 1994. Bacteriocins of lactic acid bacteria – Properties, range of inhibitory activity and methods of detection. *Food Technol Biotechnol* 32: 171-174.
540. Rolfe RD. 2000. The Role of probiotic cultures in the control of gastrointestinal health. *Microbiol* 2: 45-67.

541. Rooj AK., Kimura Y., Buddington RK. 2010. Metabolites produced by probiotic lactobacilli rapidly increase glucose uptake by Caco-2 cells. *BMC Microbiol* 10 (1): 16-26.
542. Roselli M., Finamore A., Britti MS., Mengheri E. 2006. Probiotic bacteria *Bifidobacterium animalis* MB5 and *Lactobacillus rhamnosus* GG protect intestinal Caco-2 cells from the inflammation-associated response induced by enterotoxigenic *Escherichia coli* K88. *Br J Nutr* 95: 1177-1184.
543. Roselli M., Finamore A., Britti MS., Konstantinov SR., Smidt H., de Vos WM., Mengheri E. 2007. The novel porcine *Lactobacillus sobrius* strain protects intestinal cells from enterotoxigenic *Escherichia coli* K88 infection and prevents membrane barrier damage. *J Nutr* 137: 2709-2716.
544. Roselli M., Finamore A., Nuccitelli S. 2009. Prevention of TNBS-induced colitis by different *Lactobacillus* and *Bifidobacterium* strains is associated with an expansion of *aaT* and regulatory T cells of intestinal intraepithelial lymphocytes. *Inflam Bowel Dis* 15 (10): 1526-1536.
545. Rosenberg M., Bayer EA., Delarea J., Rosenberg E. 1982. Role of thin fimbriae in adherence and growth of *Acinetobacter calcoaceticus* on hexadecane. *Appl Environ Microbiol* 44: 929-937.
546. Rosenberger CM., Finlay BB. 2003. Phagocyte sabotage: disruption of macrophage signalling by bacterial pathogens. *Nat Rev Mol Cell Biol* 4: 385-396.
547. Rosenfeldt V., Benfeldt E., Nielsen SD., Michaelsen KF., Jeppesen DL., Valerius NH., Paerregaard A. 2003. Effect of probiotic *Lactobacillus* strains in children with atopic dermatitis. *J Allergy Clin Immunol* 111 (2): 389-395.
548. Ross S., Controno G., Khan W. 1972. Resistance of *Shigella* to ampicillin and other antibiotic. *J Am Med Assoc* 221: 45-47
549. Rossi EA., Vendramine RC., Carlos IZ., Oliveira MG., Valdez GF. 2003. Efeito de um novo produto fermentado de soja sobre lípides séricos de homens adultos normocolesterolêmicos. *Arch Latin Nutr* 53: 47-50.
550. Rothwell NJ., Hopkins SJ. 1995. Cytokines and the nervous system II: action and mechanisms of action. *Trends Neurosci* 18: 130-136.
551. Rousset F., Garcia E., Defrance T., Peronne C., Vezzio N., Hsu DH., Kastelein R., Moore KW., Banchereau J. 1992. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. *Proc Natl Acad Sci USA* 89: 1890-1893.

552. Roy S., Das AB., Ghosh AN., Biswas T. 1994. Purification, pore-forming ability, and antigenic relatedness of the major outer membrane protein of *Shigella dysenteriae* type 1. *Infect Immun* 62: 4333-4338.
553. Roy S., Thanasekaran K., Dutta Roy AR., Sehgal SC. 2006. Distribution of *Shigella* enterotoxin genes and secreted autotransporter toxin gene among diverse species and serotypes of *Shigella* isolated from Andaman Islands, India. *Tropical Medicine Int Health* 11: 1694-1698.
554. Ruiz L., Hevia A., Bernardo D., Margolles A., Sánchez B. 2014. Extracellular molecular effectors mediating probiotic attributes. *FEMS Microbiol Lett* 10: 1-11.
555. Rumbo M., Nempon C., Kraehenbuhl J-P., Sirard J-C. 2006. Mucosal interplay among commensal and pathogenic bacteria: lessons from flagellin and Toll-like receptor 5. *FEBS Lett* 580: 2976-2984.
556. Rundfeldt C., Koch R., Richter A., Mevissen M., Gerecke U., Loscher W. 1995. Dose-dependent anticonvulsant and proconvulsant effects of nitric oxide synthase inhibitors on seizure threshold in a cortical stimulation model in rats. *Eur J Pharmacol* 274: 73-81.
557. Saarela M., Mogensen G., Fonden R., Matto J., Matilla ST. 2000. Probiotic bacteria: Safety, functional and technological properties. *J Biotechnol* 84: 197-215.
558. Sahoo M., Ceballos-Olvera I., del Barrio L., Re F. 2011. Role of the inflammasome, IL-1 β , and IL-18 in bacterial infections. *Sci World J* 11: 2037-2050.
559. Salam MA., Bennish ML. 1988. Therapy for shigellosis I randomized double-blind trial of nalidixic acid in childhood shigellosis. *J Pediatr* 113: 901-907.
560. Salminen S., Deighton M., Gorbach S. 1993. Lactic acid bacteria in health and disease. Marcel Dekker, Inc, New York, 199-225.
561. Salminen MK., Tynkkynen S., Rautelin H., Saxelin M., Vaara M., Ruutu P., Sarana S., Valtonen V., Jarvinen A. 2002. *Lactobacillus* bacteremia during a rapid increase in probiotic use of *Lactobacillus rhamnosus* GG in Finland. *Clin Infect Dis* 35 (10): 1155-1160.
562. Salminen MK., Rautelin H., Tynkkynen S., Poussa T., Saxelin M., Valtonen V., Jarvinen A. 2004. *Lactobacillus* bacteremia, clinical significance, and patient outcome, with special focus on probiotic *L. rhamnosus* GG. *Clin Infect Dis* 38 (1): 62-69
563. Salminen MK., Rautelin H., Tynkkynen S., Poussa T., Saxelin M., Valtonen V., Jarvinen A. 2006. *Lactobacillus* bacteremia, species identification, and antimicrobial susceptibility of 85 blood isolates. *Clin Infect Dis* 42 (5): e35-44.

564. Salva S., Villena J., Alvarez S. 2010. Immunomodulatory activity of *Lactobacillus rhamnosus* strains isolated from goat milk: impact on intestinal and respiratory infections. *Int J Food Microbiol* 141: 82-89.
565. Sanchez-Munoz F., Dominguez-Lopez A., Yamamoto-Furusho JK. 2008. Role of cytokines in inflammatory bowel disease. *World J Gastroenterol* 14: 4280-4288
566. Sanders ME. 2008. Products with probiotics. Available at www.usprobiotics.org
567. Sandvig K. 2001. Shiga toxins. *Toxicon* 39: 1629-1635.
568. Sansonetti PJ., Kopecko DJ., Formal SB. 1982. Involvement of a plasmid in the invasive ability of *Shigella flexneri*. *Infect Immun* 35 (3): 852-860.
569. Sansonetti PJ., Mounier J. 1987. Metabolic events mediating early killing of host cells infected by *Shigella flexneri*. *Microb Pathog* 3: 53-61.
570. Sansonetti PJ., Arondel J., Cavaillon JM., Huerre M. 1995. Role of IL-1 in the pathogenesis of experimental shigellosis. *J Clin Investig* 96: 884-892.
571. Sansonetti PJ., Arondel J., Cantey R., Prevost MC., Huerre M. 1996. Infection of rabbit Peyer's patches by *Shigella flexneri*: effect of adhesive or invasive bacterial phenotypes on follicle-associated epithelium. *Infect Immun* 64: 2752-2764.
572. Sansonetti PJ., Arondel J., Huerre M., Harada A., Matsushima A. 1999. Interleukin-8 controls bacterial transepithelial translocation at the cost of epithelial destruction in experimental shigellosis. *Infect Immun* 67: 1471-1480.
573. Sansonetti PJ., Phalipon A., Arondel J., Thirumalai K., Banerjee S., Akira S., Takeda K., Zychlinsky A. 2000. Caspase-1 activation of IL-1 β and IL-18 are essential for *Shigella flexneri*-induced inflammation. *Immunity* 12: 581-590.
574. Sansonetti PJ. 2006. Shigellosis: an old disease in new clothes? *PLoS Med* 3 (9): e354.
575. Santos M., Mauro S., Sanchez A., Torres JM., Marquina D. 2003. The antimicrobial properties of different strains of *Lactobacillus* spp. isolated from kefir. *System Appl Microbiol* 26: 434-437.
576. Saraiva M., O'Garra A. 2010. The regulation of IL-10 production by immune cells. *Nat Rev Immunol* 10: 170-181.
577. Sarem F., Sarem-Damerджи LO., Nicolas JP. 1996. Comparison of the adherence of three *Lactobacillus* strains to Caco-2 and Int-407 human intestinal cell lines. *Lett Appl Microbiol* 22: 439-442.
578. Sasakawa C., Kamata K., Sakai T., Murayama SY., Makino S., Yoshikawa M. 1986. Molecular alteration of the 140-megadalton plasmid associated with loss of virulence and Congo red binding activity in *Shigella flexneri*. *Infect Immun* 54: 470-475.

579. Saulnier DMA., Spinler JK., Gibson GR., Versalovic J. 2009. Mechanism of probiosis and prebiosis: Considerations for enhanced functional foods. *Curr Opin Biotechnol* 20: 135-141.
580. Savage DC. 1977. Microbial ecology of the gastrointestinal tract. *Annu Rev Microbiol.* 31: 107-133.
581. Savage DC. 1984. Adherence of the normal flora. Attachment of organisms to the gut mucosa (1), Boedeker EC Ed, Boca Raton CRC Press, 3-10.
582. Schell MA., Karmirantzou M., Snel B., Vilanova D., Berger B., Pessi G., Zwahlen M., Desiere F., Bork P., Delley M., Pridmore RD., Arigoni F. 2002. The genome sequence of *Bifidobacterium longum* reflects its adaptation to the human gastrointestinal tract. *Proc Natl Acad Sci USA* 99 (22): 14422-14427.
583. Schmidt H., Hensel M. 2004. Pathogenicity islands in bacterial pathogenesis. *Clin Microbiol Rev* 17: 14-56.
584. Schmittgen TD., Zakrajsek BA., Mills AG., Gorn V., Singer MJ., Reed MW. 2000. Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and realtime methods. *Anal Biochem* 285: 194-204.
585. Schroder K., Hertzog PJ., Ravasi T., Hume DA. 2004. Interferon- γ : an overview of signals, mechanisms and functions. *J Leukoc Biol* 75 (2): 163-189.
586. Schroeder GN., Hilbi H. 2008. Molecular pathogenesis of *Shigella* spp: Controlling Host Cell signaling, invasion, and death by type III secretion. *Clin Microbiol Rev J* 21 (1): 134-156.
587. Schwan WR., Kopecko DJ. 1997. Uptake of pathogenic intracellular bacteria into human and murine macrophages downregulates the eukaryotic 26S protease complex ATPase gene. *Infect Immun* 65 (11): 4754-4760.
588. Sears CL., Kaper JB. 1996. Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion. *Microbiol Rev* 60: 167-215.
589. Seidlein LV., Kim DR., Ali M., Lee H., Wang XY., Thiem VD., Canh DG., Chaicumpa W., Agtini MD., Hossain A., Bhutta ZA., Mason C., Sethabutr O., Talukder K., Nair GB., Deen JL., Kotloff K., Clemens J. 2006. A multi-centre study on *Shigelladiarrhoea* in six Asian countries: the disease burden, clinical manifestations, and the microbiology. *PLoS Med* 3 (9): e353.
590. Sen D., Dutta P., Deb BC., Pal SC. 1988. Nalidixic acid resistant *Shigella dysenteriae* type 1 in Eastern India. *Lancet* 332 (8616): 911-920.

591. Sen S., Mullan MM., Parker TJ., Woolner JT., Tarry SA., Hunter JO. 2002. Effect of *Lactobacillus plantarum* 299v on colonic fermentation and symptoms of irritable bowel syndrome. *Dig Dis Sci* 47: 2615-2620.
592. Shacter E. 2000. Quantification and significance of protein oxidation in biological samples. *Drug Metab Rev* 32: 307-326
593. Sharafi H., Maleki H., Ahmadian G., Shahbani ZH., Sajedinejad N., Houshmand B., Vali H., Akbari NK. 2013. Antibacterial activity and probiotic potential of *Lactobacillus plantarum* HKN01: a new insight into the morphological changes of antibacterial compound-treated *Escherichia coli* by electron microscopy. *J Microbiol Biotechnol* 23 (2): 225-236.
594. Sharpe ME., Hill LR., Lapage SP. 1973. Pathogenic lactobacilli. *J Med Microbiol* 6 (3): 281-286.
595. Shere KD., Sallustio S., Manassis A., Aversa TG., Goldberg MB. 1997. Disruption of IcsP, the major *Shigella* protease that cleaves IcsA, accelerates actin-based motility. *Mol Microbiol* 25: 451-462.
596. Shida K., Nanno M. 2008. Probiotics and immunology: separating the wheat from the chaff. *Trends Immunol* 29: 565-573.
597. Shiga K. 1897. Sekiri byogen kenkyu hokoku dai-ichi (first report on etiologic research on dysentery). *Saikingaku Zasshi* 25: 790-810.
598. Shiga K. 1898. Ueber den Dysenterie bacillus (*Bacillus dysenteriae*). *Zentralbl Bakteriol Parasitenkd Abt I Org* 24: 817-824.
599. Shiga K. 1906. Obsevation on the epidemiology of dysentery in Japan. *Philippine J Sci* 1: 485-500.
600. Shimazu T., Villena J., Tohno M., Fujie H., Hosoya S., Shimosato T., Aso H., Suda Y., Kawai Y., Saito T., Makino S., Ikegami S., Itoh H., Kitazawa H. 2012. Immunobiotic *Lactobacillus jensenii* elicit anti-inflammatory activity in porcine intestinal epithelial cells by modulating negative regulators of the tolllike receptor signaling pathway. *Infect Immun* 80: 276-288.
601. Shtrichman R., Samuel CE. 2001. The role of gamma interferon in antimicrobial immunity. *Curr Opin Microbiol* 4: 251-259.
602. Sibille Y., Marchandise FX. 1993. Pulmonary immune cells in health and disease: polymorphonuclear neutrophils. *Eur Respir J* 6: 1529-1543.
603. Sieuwerts S., Molenaar D., Van Hijum SAFT., Beerthuyzen M., Stevens MJA., Janssen PW M., Ingham CJ., De Bok FAM., De Vos WM., Van Hylckama Vlieg JET.

2010. Mixed-culture transcriptome analysis reveals the molecular basis of mixed-culture growth in *Streptococcus thermophilus* and *Lactobacillus bulgaricus*. *Appl Environ Microbiol* 76 (23): 7775-7784.
604. Singer M., Sansonetti PJ. 2004. IL-8 is a key chemokine regulating neutrophil recruitment in a new mouse model of *Shigella*-induced colitis. *J Immunol* 173: 4197-4206.
605. Singh AP., Prabha V., Rishi P. 2013. Value addition in the efficacy of conventional antibiotics by nisin against *Salmonella*. *Plos One* 8 (10): e76844.
606. Sinn DH., Song JH., Kim HJ., Lee JH., Son HJ., Chang DK. 2008. Therapeutic effect of *Lactobacillus acidophilus*-SDC 2012, 2013 in patients with irritable bowel syndrome. *Dig Dis Sci* 53: 2714-2718.
607. Sjogren J., Magnusson J., Broberg A., Schnurer J., Kenne L. 2003. Antifungal 3-hydroxy fatty acids from *Lactobacillus plantarum* MiLAB 14. *J Appl Microbiol* 69: 7554-7557.
608. Skeen JE., Bhaskar PT., Chen CC., Chen WS., Peng XD., Nogueira V., Hahn-Windgassen A., Kiyokawa H., Hay N. 2006. Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. *Cancer Cell* 10: 269-280.
609. Smits HH., Engering A., Van der Kleij D., De Jong EC., Schipper K., Van Capel TM., Zaat BA., Yazdanbakhsh M., Wierenga EA., Van Kooyk Y., Kapsenberg ML. 2005. Selective probiotic bacteria induce IL-10-producing regulatory T cells *in vitro* by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. *J Allergy Clin Immunol* 115 (6): 1260-1267.
610. Sokol CL., Barton GM., Farr AG., Medzhitov R. 2008. A mechanism for the initiation of allergen-induced T helper type 2 responses. *Nat Immunol* 9 (3): 310-318.
611. Srinivasan H., Baijyanthi M., Raksha Y. 2009. The magnitude of the drug resistant Shigellosis. *Indian J Med Microbiol* 27: 358-360.
612. Stadtman ER., Levine RL. 2000. Protein oxidation. *Ann N Y Acad Sci* 899: 191-208.
613. Starnes HF., Pearce MK., Tewari A., Yim JH., Zou JC., Abrams JS. 1990. Anti-IL-6 monoclonal antibodies protect against lethal *Escherichia coli* infection and lethal tumour necrosis factor alpha challenge in mice. *Immunol* 145: 4185-4191.
614. Steffen EK., Berg RD. 1983. Relationship between cecal population levels of indigenous bacteria and translocation to the mesenteric lymph nodes. *Infect Immun* 39: 1252-1259.

615. Steinberg D. 1995. Role of oxidized LDL and antioxidants in atherosclerosis. *Adv Exp Med Biol* 369: 39-48.
616. Strom K., Sjogren J., Broberg A., Schnurer J. 2002. *Lactobacillus plantarum* MiLAB 393 produces the antifungal cyclic dipeptidescyclo (L-Phe-L-Pr) and cyclo (L-Phe-*trans*-4-OH-L--Pro) and 3-phenyllactic acid. *Appl Environ Microbiol* 68: 4322-4327.
617. Sulkin SE., Willett JC. 1940. A triple sugar-ferrous sulfate medium for use in identification of enteric organisms. *J Lab Clin Med* 25: 649-653.
618. Sur D., Niyogi SK., Sur S., Datta KK., Takeda Y., Nair GB., Bhattacharya SK. 2003. Multi-drug resistant *Shigella dysenteriae* type 1: forerunners of a new epidemic strain in eastern India? *Emerg Inf Dis* 9 (3): 404-405.
619. Sur D., Ramamurthy T., Deen J., Bhattacharya SK. 2004. Shigellosis: challenges and management issues. *Indian J Med Res* 120: 454-62.
620. Suskovic J. 1996. Bacterial growth and probiotic activity of selected lactic acid bacteria, PhD Thesis, Faculty of Food Technology and Biotechnology, University of Zagreb, Zagreb, Croatia.
621. Suskovic J., Kos B., Goreta J., Mato S. 2001. Role of lactic acid bacteria and bifidobacteria in synbiotic effect. *Food Technol Biotechnol* 39: 227-235.
622. Suskovic J., Kos B., Beganovic J., Pavunc AL., Habjaniz K., Matosic S. 2010. Antimicrobial activity-the most important property of probiotic and starter lactic acid bacteria. *Food Technol Biotechnol* 48 (3): 296-307.
623. Szajewska H., Kotowska M., Mrukowicz JZ., Armanska M., Mikolajczyk M. 2001. Efficacy of *Lactobacillus* GG in prevention of nosocomial diarrhea in infants. *J Pediatr* 138: 361-365.
624. Takanashi N., Tomosada Y., Villena J., Murata K., Takahashi T., Chiba E., Tohno M., Shimazu T., Aso H., Suda Y., Ikegami S., Itoh H., Kawai Y., Saito J., Alvarez S., Kitazawa H. 2013. Advanced application of bovine intestinal epithelial cell line for evaluating regulatory effect of lactobacilli against heat-killed enterotoxigenic *Escherichia coli*-mediated inflammation. *BMC Microbiol* 13: 54-70.
625. Takeuchi O., Kaufmann A., Grote K., Kawai T., Hoshino K., Morr M., Muhlradt PF., Akira S. 2000. Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a Toll-like receptor 2- and MyD88-dependent signalling pathway. *J Immunol* 164: 554-557.

626. Takeuchi O., Kawai T., Muhlradt PW., Morr M., Radolf JD., Zychlinsky A., Takeda K., Akira S. 2001. Discrimination of bacterial lipoproteins by Toll like receptor 6. *Int Immunol* 13: 933-940.
627. Tallant T., Deb A., Kar N., Lupica J., de Veer MJ., DiDonato JA. 2004. Flagellin acting via TLR5 is the major activator of key signalling pathways leading to NF-kappa B and proinflammatory gene program activation in intestinal epithelial cells. *BMC Microbiol* 4: 33-57.
628. Tamano K., Aizawa S., Katayama E., Nonaka T., Imajoh-Ohmi S., Kuwae A., Nagai S., Sasakawa C. 2000. Supramolecular structure of the *Shigella* type III secretion machinery: the needle part is changeable in length and essential for delivery of effectors. *EMBO J* 19: 3876-3887.
629. Tambekar DH., Bhutada SA. 2010. Acid and bile tolerance, antibacterial activity, antibiotic resistance and bacteriocins activity of probiotic *Lactobacillus* species. *Recent Res Sci Technol* 2 (4): 94-98.
630. Tanaka H., Doseburg K., Iwasaki T., Mierau I. 1999. Screening of lactic acid bacteria for bile salt hydrolase activity. *J Dairy Sci* 82 (12): 2530-2535.
631. Tanaka A., Seki M., Yamahira S., Noguchi H., Kosai K., Toba M., Morinaga Y., Miyazaki T., Izumikawa K., Kakeya H., Yamamoto Y., Yanagihara K., Tashiro T., Kohda N., Kohno N. 2011. *Lactobacillus pentosus* strain b240 suppresses pneumonia induced by *Streptococcus pneumoniae* in mice. *Lett Appl Microbiol* 53 (1): 35-43.
632. Tandon P., Moncrief K., Madsen K., Arrieta MC., Owen RJ., Bain VG., Wong WW., Ma MM. 2009. Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study. *Liver Int* 29 (7): 1110-1115.
633. Taneja N., Lyngdoh V., Vermani A., Mohan B., Rao P., Singh M., Dogra A., Singh MP., Sharma M. 2005. The re-emergence of multi-drug resistant strains of *Shigella dysenteriae* with an added resistance to ciprofloxacin in north India and their plasmid profiles. *Indian J Med Res* 122: 348-354.
634. Taneja N. 2007. The changing epidemiology of Shigellosis and the emergence of ciprofloxacin resistant *Shigellae* in India. *J Clin Microbiol* 45: 678-679.
635. Tannock GW. 1999. Probiotics: a critical review. Horizon Scientific Press, Norfolk, UK, 5-14.

636. Tannock GW., Munro K., Harmsen HJM., Welling GW., Smart J., Gopal PK. 2000. Analysis of the fecal microflora of human subjects consuming a probiotic product containing *Lactobacillus rhamnosus* DR20. *Appl Environ Microbiol* 66: 2578-2588.
637. Tannock GW. 2005. Probiotics and prebiotics: scientific aspects. Caister Academic Press, Norfolk, UK, 51-82.
638. Taylor WI., Achanzar D. 1972. Catalase test as an aid to the identification of *Enterobacteriaceae*. *Appl microbiol* 24: 58-61.
639. Taylor D., Echeverria P., Pal T., Sethabutr O., Saiborisuth S., Sricharmorn S., Rowe B., Cross J. 1986. The role of *Shigella* spp., enteroinvasive *Escherichia coli* and other enteropathogens as cause of childhood dysentery in Thailand. *J Infect Dis* 153: 1132-1138.
640. Teitelbaum JE., Walker WA. 2002. Nutritional impact of pre and probiotics as protective gastrointestinal organisms. *Annu Rev Nutr* 22: 107-138.
641. Temblay JN., Bertelli E., Arques JL., Regoli M., Nicoletti C. 2007. Production of IL-12 by Peyer patch-dendritic cells is critical for the resistance to food allergy. *J Allergy Clin Immunol* 120 (3): 659-665.
642. Tenorio C., Zarazaga M., Martinez C., Torres C. 2001. Bifunctional enzyme 6'-N-aminoglycoside acetyltransferase-2"-O-aminoglycoside phosphotransferase in *Lactobacillus* and *Pediococcus* isolates of animal origin. *J Clin Microbiol* 39 (2): 824-825.
643. Tesh VL., Ramegowda B., Samuel JE. 1994. Purified Shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages. *Infect Immun* 62: 5085-5094.
644. Thapa BR., Ventkateswariu K., Malik AK., Panigrahi D. 1995. Shigellosis in children from north India: a clinicopathological study. *J Trop Ped* 41: 303-307.
645. Thirumala-Devi K., Lamkanfi M., Nunez G. 2007. Intracellular NOD-like receptors in host defense and disease. *Immunity* 27: 549-559.
646. Tien MT., Girardin SE., Regnault B., Le Bourhis L., Dillies MA., Coppée JY., Bourdet-Sicard R., Sansonetti PJ., Pedron T. 2006. Antiinflammatory effect of *Lactobacillus casei* on *Shigella*-infected human intestinal epithelial cells. *J Immunol* 176 (2): 1228-1237.
647. Todd C. 1904. On a dysentery toxin and antitoxin. *J Hyg* 4: 480- 494.

648. Tomas MSJ., Ocana V., Wiese B., Machias M. 2003. Growth and lactic acid production by vaginal *Lactobacillus acidophilus* CRL 1259, and inhibition of uropathogenic *Escherichia coli*. J Med Microbiol 52: 1117-1124.
649. Trebichavsky I., Rada V., Splichalova A., Splichal I. 2009. Cross-talk of human gut with bifidobacteria. Nutr Rev 67 (2): 77-82.
650. Trikha R., Kaur P., Rishi P., Malik RK., Tewari R. 2014. Synbiotics-synergistic effect of probiotics and prebiotics on human health. In: Recent developments in biotechnology vol 3: Microbial Biotechnology, Studium Press LLC, USA, 415-449.
651. Trinchieri G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133-146.
652. Tsai YT., Cheng PC., Liao JW., Pan TM. 2010. Effect of the administration of *Lactobacillus paracasei* subsp. *paracasei* NTU 101 on peyer's patch-mediated mucosal immunity. Int Immunopharmacol 10: 791-798.
653. Tulumoglu S., Yuksekdogan ZN., Beyatli Y., Simsek O., Cinar B., Yasar E. 2013. Probiotic properties of lactobacilli species isolated from children's feces. Anaerobe 24: 36-42.
654. Tuomola EM., Ouwehand AC., Salminen SJ. 1999. The effect of probiotic bacteria on the adhesion of pathogens to human intestinal mucus. FEMS Immunol Med Microbiol 26 (2): 137-142.
655. Uchida K. 2000. Role of reactive aldehyde in cardiovascular diseases. Free Radic Biol Med 28: 1685-1696.
656. Uchida K. 2003. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res 42: 318-343.
657. Usman., Hosono A. 1999. Bile tolerance, taurocholate deconjugation, and binding of cholesterol by *Lactobacillus gasseri* strains. J Dairy Sci 82: 243-248.
658. Valdez JC., Rachid M., Gobbata N., Perdigon G. 2001. Lactic acid bacteria induce apoptosis inhibition in *Salmonella typhimurium* infected macrophages. Food Agricult Immunol 13 (3): 189-197.
659. Valerio F., Lavemicocca P., Pascale M., Visconti A. 2004. Production of phenyllactic acid by lactic acid bacteria: an approach to the selection of strains contributing to food quality and preservation. FEMS Microbiol Lett 233: 289-295.
660. Valeur N., Engel P., Carbajal N., Connolly E., Ladefoged K. 2004. Colonization and immunomodulation by *Lactobacillus reuteri* ATCC 55730 in the human gastrointestinal tract. Appl Environ Microbiol 70: 1176-1181.

661. Vallabhapurapu S., Karin M. 2009. Regulation and function of NF-kappaB transcription factors in the immune system. *Annu Rev Immunol* 27: 693-733.
662. Van Baarlen P., Troost F., Van der Meer C. 2011. Human mucosal *in vivo* transcriptome responses to three *Lactobacilli* indicate how probiotics may modulate human cellular pathways. *Proc Nat Acad Sci* 108 (1): 4562-4569.
663. Van de Verg LL., Mallett CP., Collins HH., Larsen T., Hammack CC., Hale TL. 1995. Antibody and cytokine responses in a mouse pulmonary model of *Shigella flexneri* serotype 2a infection. *Infect Immun* 63: 1947-1954.
664. Vanderbergh PA. 1993. Lactic acid bacteria, their metabolic products and interference with microbial growth. *FEMS Microbiol Rev* 12: 221-238.
665. Vasiljevic T., Shah NP. 2008. Review: probiotics-from Metchnikoff to bioactives. *Int Dairy J* 18: 714-728.
666. Vaughan EE., de Vries MC., Zoetendal EG., Ben-Amor K., Akkermans AD., de Vos WM. 2002. The intestinal LABs. *Antonie Van Leeuwenhoek* 82: 341-352.
667. Veckman V., Miettinen M., Pirhonen J., Sirén J., Matikainen S., Julkunen I. 2004. *Streptococcus pyogenes* and *Lactobacillus rhamnosus* differentially induce maturation and production of Th1-type cytokines and chemokines in human monocyte-derived dendritic cells. *J Leukoc Biol* 75: 764-771.
668. Venema K., Venema G., Kok J. 1995. Lactococcal bacteriocins: mode of action and immunity. *Trends Microbiol* 3: 299-304.
669. Venturi A., Gionchetti P., Rizzello F. 1999. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. *Alimentary Pharmacol Therapeutics* 13 (8): 1103-1108.
670. Verdu EF., Bercik P., VermaGandhu M., Huang XX., Blennerhassett P., Jackson W., Mao Y., Wang L., Rochat F., Collins SM. 2006. Specific probiotic therapy attenuates antibiotic-induced visceral hypersensitivity in mice. *Gut* 55: 182-190.
671. Villena J., Kitazawa H. 2014. Modulation of intestinal TLR4-inflammatory signalling pathways by probiotic microorganisms: lessons learned from *Lactobacillus jensenii* TL2937. *Front Immunol* 4: 512.
672. Villena J., Racedo S., Agüero G., Bru E., Medina M., Alvarez S. 2005. *Lactobacillus casei* improves resistance to pneumococcal respiratory infection in malnourished mice. *J Nutr* 135: 1462-1469.

673. Vinderola G., Matar C., Perdigon G. 2005. Role of intestinal epithelial cells in immune effects mediated by Gram-positive probiotic bacteria: involvement of Toll-Like Receptors. *Clin Diagnostic Lab Immunol* 12 (9): 1075-1084.
674. Vinh H., Baker S., Campbell J., Hoang NV., Loan HT., Chinh MT., Anh VT., Dip TS., Phuong le T., Schultsz C., Farrar J. 2009. The rapid emergence of third generation cephalosporin resistant *Shigella* spp. in southern Vietnam. *J Med Microbiol* 58 (2): 281-283.
675. Vliagoftis H., Kouranos VD., Betsi GI., Falagas ME. 2008. Probiotics for the treatment of allergic rhinitis and asthma: Systematic review of randomized controlled trials. *Ann Allergy Asthma Immunol* 101 (6): 570-579.
676. Vlkova E., Rada V., Smehilova M., Killer J. 2008. Autoaggregation and Co-aggregation ability in *Bifidobacterium* and *Clostridium*. *FoliaMicrobiologica* 53 (3): 263-269.
677. Walter J., Tannock GW., Tilsala-Timisjarvi A., Rodtong S., Loach DM., Munro K., Alatossava T. 2000. Detection and identification of gastrointestinal *Lactobacillus* species by using denaturing gradient gel electrophoresis and species-specific PCR primers. *Appl Environ Microbiol* 66 (1): 297-303.
678. Wan YY., Flavell RA. 2006. The roles for cytokines in the generation and maintenance of regulatory T cells. *Immunol Rev* 212: 114-130.
679. Wang Y., Xu Z. 2004. Probiotics treatment as method of biocontrol in aquaculture. *Feed Res* 12: 42-45.
680. Wang B., Wei H., Yuan J., Li Q., Li Y., Li N., Li J. 2008. Identification of a surface protein from *Lactobacillus reuteri* JCM1081 that adheres to porcine gastric mucin and human enterocyte-like HT-29 Cells. *Curr Microbiol* 57 (1): 33-38.
681. Way SS., Borczuk AC., Dominitz R., Goldberg MB. 1998. An essential role for gamma interferon in innate resistance to *Shigella flexneri* infection. *Infect Immun* 66: 1342-1348.
682. Weinstein DL., O'Neill BL., Metcalf ES. 1997. *Salmonella typhi* stimulation of human intestinal epithelial cell induces secretion of epithelial cell-derived interleukin-6. *Infect Immun* 65: 395-404.
683. Weisburg WG., Barns SM., Pelletier DA., Lane DJ. 1991. 16S ribosomal DNA amplification for phylogenetic study. *J Bacteriol* 173 (2): 697-703.
684. Whorwell PJ., Altringer L., Morel J., Bond Y., Charbonneau D., O'Mahony L., Kiely B., Shanahan F., Quigley EM. 2006. Efficacy of an encapsulated probiotic

- Bifidobacterium infantis* 35624 in women with irritable bowel syndrome. *Am J Gastroenterol* 101 (7): 1581-90.
685. Williams PJ., Anderson PA. 2006. Operational cost savings in dairy plant water usage. *Int J Dairy Tech* 59: 147-154.
686. Wills ED. 1996. Mechanisms of lipid peroxide formation in animal tissues. *Biochem J* 99 (3): 667-676.
687. Windsor AC., Mullen PG., Fowler AA., Sugerman HJ. 1993. Role of the neutrophil in adult respiratory distress syndrome. *Br J Surg* 80: 10-17
688. Winterbourn CC., Vissers MC., Kettle AJ. 2000. Myeloperoxidase. *Curr Opin Hematol* 7: 53-58.
689. Wollowski I., Rechkemmer G., Pool-Zobel BL. 2001. Protective role of probiotics and prebiotics in colon cancer. *Am J Clin Nutr* 73 (2): 451-455.
690. World Health Organization. 2002. Working group report on drafting guidelines for the evaluation of probiotics in food. Food administration Organization and World Health Organization, Geneva, Switzerland. Available on (http://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf).
691. World Health Organization. 2005. Shigellosis: disease burden, epidemiology and case management. *Wkly Wpidemiol Rec* 80: 94-99.
692. World Health Organization. 2005a. Guidelines for the Control of Shigellosis, including epidemics due to *Shigella dysenteriae* type 1. World Health Organization, Geneva, Switzerland. Available from: <http://whqlibdoc.who.int/publications/2005/9241592330>.
693. World Health Organization. 2005b. Shigellosis: disease burden, epidemiology and case management. World Health Organization, Geneva, Switzerland. Available from <http://apps.who.int/iris/handle/10665/73156>.
694. World Health Organization. 2006. Initiative for vaccine research (IVR). New vaccines against infectious diseases: research and development status. World Health Organization, Geneva, Switzerland. Available from http://www.who.int/vaccine_research/en/.
695. World Health Organization. 2008. The global burden of disease: 2004 update. World Health Organization, library Cataloguing-in-publication data, Geneva, Switzerland. Available from www.who.int/evidence/bod.
696. Wright NA., Hoffmann W., Otto WR., Rio MC., Thim L. 1997. Rolling in the clover: trefoil factor family (TFF)-domain peptides, cell migration and cancer. *FEBS Lett* 408: 121-123.

697. Wyllie DH., Kiss-Toth E., Visintin A., Smith SC., Boussouf S., Segal DM., Duff GW., Dower SK. 2000. Evidence for an accessory protein function for toll-like receptor 1 in anti-bacterial responses. *J Immunol* 165 (12): 7125-7132.
698. Xing HC., Li LJ., Xu KJ., Shen T., Chen YB., Sheng JF., Chen Y., Fu SF., Chen CL., Wang JG., Yan D., Dai FW., Zheng SS. 2006. Protective role of supplement with foreign *Bifidobacterium* and *Lactobacillus* in experimental ischemia-reperfusion injury. *J Gastroen Hepatol* 21: 647-656.
699. Xu H., Jeong HS., Lee Y., Ahn J. 2009. Assessment of cell surface properties and adhesion potential of selected probiotic strains. *Lett Appl Microbiol* 49 (4): 434-442.
700. Yamahira S., Toba M., Kishi K., Okamatsu H. 2006. Stimulation of mucosal immune system by lactic acid bacteria originating in tea. *Jpn J Lactic Acid Bact* 17: 57-60.
701. Yan F., Polk DB. 2002. Probiotic bacterium prevents cytokine induced apoptosis in intestinal epithelial cells. *J Biol Chem* 277: 50959-50965.
702. Yan-Ni Ping-Lan LV. 2005. Optimization of Bacteriocin Produced by *Lactobacillus pentosus* 31-1. *Microbiol* 3: Q939-Q997.
703. Yasunori O., Fayyaz S., Sutterwala RAF. 2006. The inflammasome: first line of the immune response to cell stress. *Cell* 126: 659-662.
704. Yuhas Y., Kaminsky E., Mor M., Ashkenazi S. 1996. Induction of nitric oxide production in mouse macrophages by Shiga toxin. *J Med Microbiol* 45: 97-102.
705. Zboril V. 2002. Physiology of microflora in the digestive tract. *Vnitr Lek* 48: 17-21.
706. Zeuthen LH., Christensen HR., Frokiaer H. 2006. Lactic acid bacteria inducing a weak interleukin-12 and tumor necrosis factor alpha response in human dendritic cells inhibit strongly stimulating lactic acid bacteria but act synergistically with Gram-negative bacteria. *Clin Vaccine Immunol* 13: 365-375.
707. Zeuthen LH., Fink LN., Frokiaer H. 2008. Epithelial cells prime the immune response to an array of gut-derived commensals towards a tolerogenic phenotype through distinct actions of thymic stromal lymphopoietin and transforming growth factor- α . *Immunol* 123: 197-208.
708. Zhang L., Li N., Caicedo R., Neu J. 2005. Alive and dead *Lactobacillus rhamnosus* GG decrease tumor necrosis factor-alpha-induced interleukin-8 production in Caco-2 cells. *J Nutr* 135: 1752-1756
709. Zhang Y., Zhang L., Du M., Yi H., Guo C., Tuo Y., Han X., Li J., Zhang L., Yang L. 2011. Antimicrobial activity against *Shigella sonnei* and probiotic properties of wild lactobacilli from fermented food. *Microbiol Res* 167 (1): 27-31.

710. Zhou JS., Pillidge CJ., Gopal PK., Gill HS. 2005. Antibiotic susceptibility profiles of new probiotic *Lactobacillus* and *Bifidobacterium* strains. *Int J Food Microbiol* 98: 211-217.
711. Zhu YH., Li YQ., Zhang., Zhou D., Liu H., Wang J. 2014. Dose-dependent effects of *Lactobacillus rhamnosus* on serum interleukin-17 production and intestinal T-cell responses in pigs challenged with *Escherichia coli*. *Appl Environ Microbiol* 80 (5): 1787-1798.
712. Zurawski DV., Mummy KL., Faherty CS., McCormick BA., Maurelli AT. 2009. *Shigella flexneri* type III secretion system effectors OspB and OspF target the nucleus to downregulate the host inflammatory response via interactions with retinoblastoma protein. *Mol Microbiol* 71: 350-368.
713. Zychlinsky A., Pre´vost MC., Sansonetti PJ. 1992. *Shigella flexneri* induces apoptosis in infected macrophages. *Nutr* 358: 167-168.
714. Zychlinsky A., Kenny B., Menard R., Prevost MC., Holland IB., Sansonetti PJ. 1994. IpaB mediates macrophage apoptosis induced by *Shigella flexneri*. *Mol Microbiol* 11: 619-627.
715. Zychlinsky A., Thirumalai K., Arondel J., Cantey JR., Aliprantis AO., Sansonetti PJ. 1996. *In vivo* apoptosis in *Shigella flexneri* infections. *Infect Immun* 64: 5357-5365.